EOC ID:

Actimmune-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

therapy		
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested medication: *		
Chronic granulomatous disease		
Malignant osteoporosis (severe)		
Q4. If the patient's diagnosis is OTHER, please specify below:		

Actimmune-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
---------------	------------------

EOC ID:

Adempas-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing	therapy?
☐ Initial therapy	Continuing therapy
Q2. For CONTINUING THERAPY, ple	ase provide the start date (MM/YY):
Q3. Please indicate the patient's diagnos	is for the requested medication:
Chronic thromboembolic pulmonar	y hypertension (CTEPH) (World Health Organization group 4)
 Pulmonary arterial hypertension (P Other 	PAH) (World Health Organization group 1)
Q4. For a diagnosis of CTEPH, please	select all that apply:
Patient has persistent or recurrent	ent disease after surgical treatment (e.g. pulmonary endarterectomy)
Patient's disease is inoperable	
None of the above	
Q5. For a diagnosis of PAH, was the d	iagnosis confirmed by right heart catheterization?
Yes	□ No
Q6. If the patient's diagnosis is OTHER	२, please specify below:
Q7. If the patient is FEMALE, is she enrolled in the ADEMPAS REMS program?	

EOC ID:

Adempas-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
 ☐ Yes ☐ No ☐ N/A - the patient is not female 	
Q8. Is the patient 18 years of age or older?	
☐ Yes	□ No

Prescriber Signature

Date

EOC ID:

ADHD-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
☐ Initial therapy	Continuing therapy
Q2. If the request is for CONTINUING THERAPY, please p	provide the start date (MM/YY):
Q3. Please indicate which medication is being requested:	
Amphetamine-dextroamphetamine ER	
🗌 Daytrana Patch	
Dextroamphetamine ER	
Dextroamphetamine IR	
Methylphenidate	
Q4. Please indicate the patient's diagnosis for the requested	medication:
Attention deficit disorder (ADD)	
Attention Deficit Hyperactivity disorder (ADHD)	
Narcolepsy	
Other	
Q5. For NARCOLEPSY, have sleep studies been complete	ed which support the diagnosis?
☐ Yes	□ No

EOC ID:

ADHD-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Q6. If the patient's diagnosis is OTHER, please specify	v below:	
Q7. Please indicate the patient's age below:		
Under 3 years 3-5 years	☐ 6 years or older	
Q8. Has the prescriber considered the benefits of use ver	sus the potential risks of serious cardiovascular events?	
☐ Yes	□ No	
Q9. Will the patient be using an MAOI concurrently with the requested medication, or within the last 14 days?		
☐ Yes	□ No	
Q10. Is the prescriber a psychiatrist with experience prescribing both MAOI and amphetamine/dextroamphetamine drugs?		
☐ Yes	□ No	

Prescriber Signature

Date

EOC ID:

Alecensa-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the star	t date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested medication: *		
Non-small cell lung cancer (NSCLC), metastatic	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the patient's disease anaplastic lymphoma kinase (ALK)- positive?		
	No	

EOC ID:

Alecensa-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
Prescriber Signature	Date

EOC ID:

Alpha-1 Proteinase Inhibitor-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Alpha-1-antitrypsin (AAT) deficiency	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the patient 18 years of age or older?		
	□ No	
Q6. Please select all that apply for this patient:		
The alpha1-proteinase inhibitor concentration is less th		
The patient's FEV1 level is between 35% and 60% pre-		
The patient's FEV1 level is greater than 60% predicted		
None of the above		
Q7. IF THE FEV1 IS GREATER THAN 60% PREDICTED, (i.e., reduction of FEV1 more than 120 mL/year) that warra	has the patient experienced a rapid decline in lung function nts treatment?	
L		

EOC ID:

Alpha-1 Proteinase Inhibitor-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
☐ Yes	□ No	
Q8. Does the patient have IgA deficiency with antibodies against IgA?		
☐ Yes	□ No	

Prescriber Signature

Date

EOC ID:

Alunbrig-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
☐ Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start	adate (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Non-small cell lung cancer (NSCLC), metastatic	Other	
Q4. For NSCLC, is the patient anaplastic lymphoma kinase	e (ALK)-positive?	
☐ Yes	□ No	
Q5. If the patient's diagnosis is OTHER, please specify below:		
Q6. Has the patient experienced disease progression on (or is intolerant to) crizotinib (Xalkori)?		
	□ No	
Q7. Is the patient 18 years of age or older?		
☐ Yes	□ No	
Q8. Is the requested medication being prescribed by (or in consultation with) an oncologist?		

EOC ID:

Alunbrig-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
☐ Yes	□ No

Prescriber Signature

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Date

EOC ID:

Ampyra-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please specify the start	date (MM/YY):	
O2. Diagon indicate the notiont's diagnosis for the requested	modiaction: *	
Q3. Please indicate the patient's diagnosis for the requested		
Multiple sclerosis (MS)	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Has patient demonstrated sustained walking impairment, assistance) prior to starting Ampyra?	but with the ability to walk 25 feet (with or without	
☐ Yes	□ No	
Q6. Is the patient 18 years of age or older?		
☐ Yes	□ No	
Q7. Is the requested medication being prescribed by (or in consultation with) a neurologist?		
☐ Yes	□ No	
Q8. Does the patient have any of the following (please select all that apply)?		

EOC ID:

Ampyra-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
 History of seizure Moderate or severe renal impairment (creatinine c None of the above 	learance less than or equal to 50 mL/minute)

Prescriber Signature

Date

EOC ID:

Analeptics-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy? Initial therapy Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY): Q3. Please indicate which medication this request is for: Armodafinil Q4. For MODAFINIL, is the patient 17 years of age or older? Yes Yes Excessive sleepiness associate with narcolepsy Excessive sleepiness associate with narcolepsy Excessive sleepiness associate with obstructive sleep apnea/hypopnea syndrome (OSA/HS) Other			
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY): Q3. Please indicate which medication this request is for: Armodafinil Q4. For MODAFINIL, is the patient 17 years of age or older? Yes Q5. Please indicate the patient's diagnosis for the requested medication: * Excessive sleepiness associate with narcolepsy Excessive sleepiness associated with shift work sleep disorder (SWSD) Excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSA/HS) Other Q6. For NARCOLEPSY, has the patient tried and failed (or had a contraindication or intolerance to) at least one other central nervous system stimulant (such as methylphenidate, mixed amphetamine salts, dextroamphetamine)? Yes No	Q1. Is this request for initial or continuing therapy?		
Q3. Please indicate which medication this request is for: Armodafinil Q4. For MODAFINIL, is the patient 17 years of age or older? Yes Q5. Please indicate the patient's diagnosis for the requested medication: * Excessive sleepiness associate with narcolepsy Excessive sleepiness associated with shift work sleep disorder (SWSD) Excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSA/HS) Other Q6. For NARCOLEPSY, has the patient tried and failed (or had a contraindication or intolerance to) at least one other central nervous system stimulant (such as methylphenidate, mixed amphetamine salts, dextroamphetamine)? Yes No	Initial therapy	Continuing therapy	
Armodafinil Modafinil Q4. For MODAFINIL, is the patient 17 years of age or older? No Yes No Q5. Please indicate the patient's diagnosis for the requested medication: * Excessive sleepiness associate with narcolepsy Excessive sleepiness associated with shift work sleep disorder (SWSD) Excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSA/HS) Other Q6. For NARCOLEPSY, has the patient tried and failed (or had a contraindication or intolerance to) at least one other central nervous system stimulant (such as methylphenidate, mixed amphetamine salts, dextroamphetamine)? Yes No	Q2. If the request is for CONTINUING THERAPY, please	provide the start date (MM/YY):	
Armodafinil Modafinil Q4. For MODAFINIL, is the patient 17 years of age or older? No Yes No Q5. Please indicate the patient's diagnosis for the requested medication: * Excessive sleepiness associate with narcolepsy Excessive sleepiness associated with shift work sleep disorder (SWSD) Excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSA/HS) Other Q6. For NARCOLEPSY, has the patient tried and failed (or had a contraindication or intolerance to) at least one other central nervous system stimulant (such as methylphenidate, mixed amphetamine salts, dextroamphetamine)? Yes No			
Q4. For MODAFINIL, is the patient 17 years of age or older? Yes No Q5. Please indicate the patient's diagnosis for the requested medication: * Excessive sleepiness associate with narcolepsy Excessive sleepiness associated with shift work sleep disorder (SWSD) Excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSA/HS) Other Q6. For NARCOLEPSY, has the patient tried and failed (or had a contraindication or intolerance to) at least one other central nervous system stimulant (such as methylphenidate, mixed amphetamine salts, dextroamphetamine)? Yes No	Q3. Please indicate which medication this request is for:		
☐ Yes ☐ No Q5. Please indicate the patient's diagnosis for the requested medication: *	Armodafinil	Modafinil	
Q5. Please indicate the patient's diagnosis for the requested medication: *	Q4. For MODAFINIL, is the patient 17 years of age or olde	er?	
 Excessive sleepiness associate with narcolepsy Excessive sleepiness associated with shift work sleep disorder (SWSD) Excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSA/HS) Other Q6. For NARCOLEPSY, has the patient tried and failed (or had a contraindication or intolerance to) at least one other central nervous system stimulant (such as methylphenidate, mixed amphetamine salts, dextroamphetamine)? Yes 	☐ Yes	□ No	
 Excessive sleepiness associated with shift work sleep disorder (SWSD) Excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSA/HS) Other Q6. For NARCOLEPSY, has the patient tried and failed (or had a contraindication or intolerance to) at least one other central nervous system stimulant (such as methylphenidate, mixed amphetamine salts, dextroamphetamine)? Yes 	Q5. Please indicate the patient's diagnosis for the requested medication: *		
 Excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome (OSA/HS) Other Q6. For NARCOLEPSY, has the patient tried and failed (or had a contraindication or intolerance to) at least one other central nervous system stimulant (such as methylphenidate, mixed amphetamine salts, dextroamphetamine)? Yes 	Excessive sleepiness associate with narcolepsy		
 ☐ Other Q6. For NARCOLEPSY, has the patient tried and failed (or had a contraindication or intolerance to) at least one other central nervous system stimulant (such as methylphenidate, mixed amphetamine salts, dextroamphetamine)? ☐ Yes ☐ No 	Excessive sleepiness associated with shift work sleep disorder (SWSD)		
central nervous system stimulant (such as methylphenidate, mixed amphetamine salts, dextroamphetamine)?		p apnea/hypopnea syndrome (OSA/HS)	
Q7. For SWSD, please select all that apply to this patient:	☐ Yes	□ No	
	Q7. For SWSD, please select all that apply to this patient:		

EOC ID:

Analeptics-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
 The patient experiences excessive sleepiness f The patient experiences excessive sleepiness v None of the above 	
Q8. If the patient's diagnosis is OTHER, please specify	/ below:

Prescriber Signature

Date

EOC ID:

Arcalyst-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy? Initial therapy Q2. For CONTINUING THERAPY, please specify the start date (MM/YY): Q3. For CONTINUING THERAPY, has the patient's condition improved or stabilized? Yes No Q4. Please indicate the patient's diagnosis for the requested medication: Cryopyrin-associated periodic syndrome (CAPS) Q5. If the patient's diagnosis is OTHER, please specify below: Q6. Is the patient 12 years of age or older? Yes Or. Does the patient have any of the following (please select all that apply)? Active infection Chronic infection Chronic infection Oncourrent therapy with other biologics		
Q2. For CONTINUING THERAPY, please specify the start date (MM/YY): Q3. For CONTINUING THERAPY, has the patient's condition improved or stabilized? Yes No Q4. Please indicate the patient's diagnosis for the requested medication: Cryopyrin-associated periodic syndrome (CAPS) Q5. If the patient's diagnosis is OTHER, please specify below: Q6. Is the patient 12 years of age or older? Yes Q7. Does the patient have any of the following (please select all that apply)? Active infection Chronic infection Concurrent therapy with other biologics	Q1. Is this request for initial or continuing therapy?	
Q3. For CONTINUING THERAPY, has the patient's condition improved or stabilized? Yes No Q4. Please indicate the patient's diagnosis for the requested medication: Cryopyrin-associated periodic syndrome (CAPS) Other Q5. If the patient's diagnosis is OTHER, please specify below: Q6. Is the patient 12 years of age or older? Yes No Q7. Does the patient have any of the following (please select all that apply)? Active infection Chronic infection Concurrent therapy with other biologics	Initial therapy	Continuing therapy
□ Yes □ No Q4. Please indicate the patient's diagnosis for the requested medication: □ □ Cryopyrin-associated periodic syndrome (CAPS) □ Other Q5. If the patient's diagnosis is OTHER, please specify below: □ Q6. Is the patient 12 years of age or older? □ No Q7. Does the patient have any of the following (please select all that apply)? □ Active infection □ Chronic infection □ Concurrent therapy with other biologics	Q2. For CONTINUING THERAPY, please specify the start	t date (MM/YY):
□ Yes □ No Q4. Please indicate the patient's diagnosis for the requested medication: □ □ Cryopyrin-associated periodic syndrome (CAPS) □ Other Q5. If the patient's diagnosis is OTHER, please specify below: □ Q6. Is the patient 12 years of age or older? □ No Q7. Does the patient have any of the following (please select all that apply)? □ Active infection □ Chronic infection □ Concurrent therapy with other biologics		
Q4. Please indicate the patient's diagnosis for the requested medication: Cryopyrin-associated periodic syndrome (CAPS) Other Q5. If the patient's diagnosis is OTHER, please specify below: Q6. Is the patient 12 years of age or older? Yes No Q7. Does the patient have any of the following (please select all that apply)? Active infection Chronic infection Concurrent therapy with other biologics	Q3. For CONTINUING THERAPY, has the patient's condit	tion improved or stabilized?
□ Cryopyrin-associated periodic syndrome (CAPS) □ Other Q5. If the patient's diagnosis is OTHER, please specify below: Q6. Is the patient 12 years of age or older? □ Yes □ No Q7. Does the patient have any of the following (please select all that apply)? □ Active infection □ Chronic infection □ Concurrent therapy with other biologics	☐ Yes	□ No
Q5. If the patient's diagnosis is OTHER, please specify below: Q6. Is the patient 12 years of age or older? Pres No Q7. Does the patient have any of the following (please select all that apply)? Active infection Chronic infection Concurrent therapy with other biologics	Q4. Please indicate the patient's diagnosis for the requested	medication:
Q6. Is the patient 12 years of age or older? Pes Q7. Does the patient have any of the following (please select all that apply)? Active infection Chronic infection Concurrent therapy with other biologics	Cryopyrin-associated periodic syndrome (CAPS)	Other
 Yes No Q7. Does the patient have any of the following (please select all that apply)? Active infection Chronic infection Concurrent therapy with other biologics 	Q5. If the patient's diagnosis is OTHER, please specify be	low:
Q7. Does the patient have any of the following (please select all that apply)? Active infection Chronic infection Concurrent therapy with other biologics	Q6. Is the patient 12 years of age or older?	
 Active infection Chronic infection Concurrent therapy with other biologics 	☐ Yes	□ No
 Chronic infection Concurrent therapy with other biologics 	Q7. Does the patient have any of the following (please select	t all that apply)?
Concurrent therapy with other biologics	Active infection	
	□ None of the above	

EOC ID:

Arcalyst-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Prescriber Signature

Date

EOC ID:

Arikayce-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
Initial therapy	Continuing therapy
Q2. For CONTINUING THERAPY, please provide the star	t date (MM/YY):
Q3. Please indicate the patient's diagnosis for the requested	medication:
Pulmonary Mycobacterium avium complex (MAC) infection	Other
Q4. If the patient's diagnosis is OTHER, please specify be	low:
Q5. Will Arikayce be used in combination with other antibacted	erial drugs?
☐ Yes	□ No
Q6. Has the patient been treated for 6 consecutive months w	ith multidrug background regimen therapy?
☐ Yes	□ No
Q7. Has the patient achieved negative sputum cultures fro	m prior treatment?
☐ Yes	□ No
Q8. Is the patient 18 years of age or older?	

EOC ID:

Arikayce-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
Yes	□ No
Q9. Is the requested medication being prescribed by (or in pulmonologist?	n consultation with) an infectious disease specialist or
Yes	□ No

Prescriber Signature

Date

EOC ID:

Atypical Antipsychotics-12 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy? Initial therapy Q2. For CONTINUING THERAPY, please provide the start date (MM/YY): Q3. Please indicate which medication this request is for: Fanapt Saphris Vraylar Q4. Please indicate the patient's diagnosis for the requested medication: Bipolar I disorder (manic or mixed episodes) Dementia-related psychosis only Schizophrenia Other Q5. If the patient's diagnosis is OTHER, please specify below: Q6. Please indicate the patient's age below: Index 10 years of age 10-17 years of age 56 years of age or older				
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY): Q3. Please indicate which medication this request is for: □ Fanapt □ Saphris Q4. Please indicate the patient's diagnosis for the requested medication: □ Bipolar I disorder (manic or mixed episodes) □ Dementia-related psychosis only □ Schizophrenia □ Other Q5. If the patient's diagnosis is OTHER, please specify below: Q6. Please indicate the patient's age below: □ Under 10 years of age □ 10-17 years of age □ 18-64 years of age	Q1. Is this request for initial or	continuing therapy?		
Q3. Please indicate which medication this request is for: □ Fanapt □ Saphris Q4. Please indicate the patient's diagnosis for the requested medication: □ Bipolar I disorder (manic or mixed episodes) □ Dementia-related psychosis only □ Schizophrenia □ Other Q5. If the patient's diagnosis is OTHER, please specify below: Q6. Please indicate the patient's age below: □ Under 10 years of age □ 10-17 years of age □ 18-64 years of age	Initial therapy		Continuing therapy	
Fanapt Saphris Vraylar Q4. Please indicate the patient's diagnosis for the requested medication: Bipolar I disorder (manic or mixed episodes) Dementia-related psychosis only Schizophrenia Other Other Q5. If the patient's diagnosis is OTHER, please specify below: Q6. Please indicate the patient's age below: Under 10 years of age 10-17 years of age 18-64 years of age	Q2. For CONTINUING THE	RAPY, please provide the start date	(MM/YY):	
Fanapt Saphris Vraylar Q4. Please indicate the patient's diagnosis for the requested medication: Bipolar I disorder (manic or mixed episodes) Dementia-related psychosis only Schizophrenia Other Other Q5. If the patient's diagnosis is OTHER, please specify below: Q6. Please indicate the patient's age below: Under 10 years of age 10-17 years of age 18-64 years of age				
Q4. Please indicate the patient's diagnosis for the requested medication: Bipolar I disorder (manic or mixed episodes) Dementia-related psychosis only Schizophrenia Other Q5. If the patient's diagnosis is OTHER, please specify below: Q6. Please indicate the patient's age below: Under 10 years of age 10-17 years of age 18-64 years of age	Q3. Please indicate which med	lication this request is for:		
 ☐ Bipolar I disorder (manic or mixed episodes) ☐ Dementia-related psychosis only ☐ Schizophrenia ☐ Other Q5. If the patient's diagnosis is OTHER, please specify below: Q6. Please indicate the patient's age below: ☐ Under 10 years of age ☐ 10-17 years of age ☐ 18-64 years of age 	☐ Fanapt	Saphris	🗌 Vraylar	
 Dementia-related psychosis only Schizophrenia Other Q5. If the patient's diagnosis is OTHER, please specify below: Q6. Please indicate the patient's age below: Under 10 years of age 10-17 years of age 18-64 years of age 	Q4. Please indicate the patient	's diagnosis for the requested medic	ation:	
 ☐ Schizophrenia ☐ Other Q5. If the patient's diagnosis is OTHER, please specify below: Q6. Please indicate the patient's age below: ☐ Under 10 years of age ☐ 10-17 years of age ☐ 18-64 years of age 	Bipolar I disorder (manic	; or mixed episodes)		
 ☐ Other Q5. If the patient's diagnosis is OTHER, please specify below: Q6. Please indicate the patient's age below: ☐ Under 10 years of age ☐ 10-17 years of age ☐ 18-64 years of age 		osis only		
Q5. If the patient's diagnosis is OTHER, please specify below: Q6. Please indicate the patient's age below: Under 10 years of age 10-17 years of age 18-64 years of age				
Q6. Please indicate the patient's age below: Under 10 years of age 10-17 years of age 18-64 years of age				
 Under 10 years of age 10-17 years of age 18-64 years of age 	Q5. If the patient's diagnosis is OTHER, please specify below:			
 Under 10 years of age 10-17 years of age 18-64 years of age 				
 10-17 years of age 18-64 years of age 	Q6. Please indicate the patient	's age below:		
18-64 years of age	Under 10 years of age			
	☐ 10-17 years of age			
65 years of age or older				
	65 years of age or older			

EOC ID:

Atypical Antipsychotics-12 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Q7 Has the patient tried and failed (or has a documented intolerance or contraindication to) any of the following		1

	of any of the following
(please select all that apply)?	
Aripiprazole	
Olanzapine	
Risperidone	
Quetiapine	
Ziprasidone	
None of the above	

Prescriber Signature

Date

EOC ID:

Auryxia-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
Initial therapy	Continuing therapy
Q2. For CONTINUING THERAPY, please provide the start da	ite (MM/YY):
Q3. Please indicate the patient's diagnosis for the requested r	nedication:
Hyperphosphatemia	
Iron deficiency anemia	
Other	
Q4. Does the patient have chronic kidney disease (CKD)?	
☐ Yes	□ No
Q5. Is the patient on dialysis?	
	□ No
Q6. Is the patient 18 years of age or older?	
	□ No

EOC ID:

Auryxia-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Austedo-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

14	
Q6. If the patient's diagnosis is OTHER, please specify below:	
14	

EOC ID:

Austedo-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Q8. Is the requested medication being prescribed by (or in consultation with) a psychiatrist or neurologist?		
Yes	□ No	
Q9. Does the patient have any of the following (please select all that apply)?		
Any degree of hepatic impairment or hepatic disease		
Active suicidal ideation		
Untreated or inadequately treated depression		
□ None of the above		

Prescriber Signature

Date

EOC ID:

Bosulif-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
☐ Initial therapy	Continuing therapy
Q2. If the request is for CONTINUING THERAP	Y, please provide the start date (MM/YY):
Q3. Please indicate the patient's diagnosis for the r	requested medication:
	nic myelogenous leukemia (CML) (chronic, accelerated, or blast phase) nic myelogenous leukemia (CML) (newly diagnosed chronic phase)
	RATED, OR BLAST PHASE, has the patient had resistance, relapse, e of the following tyrosine kinase inhibitors (TKI) (please select all that
Gleevec (imatinib)	
Sprycel (dasatinib)	
Tasigna (nilotinib)	
None of the above	
	edications listed in the previous question, is there a reason these ation, history of adverse event, disease is resistant or intolerant,

EOC ID:

Bosulif-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Q6. If the patient's diagnosis is OTHER, please specify below:		
Q7. Is the patient at least 18 years of age or older?		
☐ Yes	No	

Prescriber Signature

Date

EOC ID:

Braftovi-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name ((if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start da	ate (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested in	nedication:	
Melanoma (unresectable or metastatic)	☐ Other	
Q4. If the patient's diagnosis is OTHER, please specify below		
Q5. Does the patient have BRAF V600E or V600K mutation a	s detected by an FDA-approved test?	
☐ Yes	□ No	
Q6. Will Braftovi be used in combination with Mektovi (binimetinib)?		
☐ Yes	□ No	
Q7. Is the requested medication being prescribed by (or in consultation with) an oncologist?		
☐ Yes	□ No	
Q8. Is the patient 18 years of age or older?		

EOC ID:

Braftovi-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
☐ Yes	□ No

Prescriber Signature

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Date

EOC ID:

Cabometyx-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. Is this request for initial or continuing thera	ipy?	
Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THEF	RAPY, please provide the start date (MM/YY):	
Q3. Please indicate the patient's diagnosis for	the requested medication:	
Renal cell carcinoma (advanced)	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the patient 18 years of age or older?		
☐ Yes	□ No	

Prescriber Signature

Date

EOC ID:

Cabometyx-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
Prescriber Signature	Date

EOC ID:

Calquence-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?				
Initial therapy	Continuing therapy			
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY):				
Q3. Please indicate the patient's diagnosis for the requested medication:				
Mantle cell lymphoma (MCL)	Other			
Q4. If the patient's diagnosis is OTHER, please specify below:				
Q5. Has the patient received at least one (1) prior therapy for MCL?				
	□ No			
Q6. Is Calquence being prescribed by (or in consultation with) an oncologist?				
	□ No			
Q7. Is the patient 18 years of age or older?				
☐ Yes	□ No			

EOC ID:

Calquence-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Cayston-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?			
Initial therapy	Continuing therapy		
Q2. For CONTINUING THERAPY, please indicate the start date (MM/YY):			
Q3. For CONTINUING THERAPY, please select all that apply:			
The patient is benefitting from treatment (for example, improvement in lung function [FEV1], decreased number of pulmonary exacerbations)			
There is clinical reason to continue therapy (such as symptomatic improvement or pulmonary function tests			
have not deteriorated more than 10% from baseline)			
Q4. Please indicate that patient's diagnosis for the requested	medication:		
Cystic fibrosis (CF)	Other		
Q5. If the patient's diagnosis is OTHER, please specify below:			
Q6. Has the diagnosis been confirmed by appropriate diagnostic or genetic testing?			
☐ Yes	□ No		
Q7. Does the patient have evidence of P. aeruginosa in the lungs as confirmed by cultures of the airways?			

EOC ID:

Cayston-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
☐ Yes	□ No
Q8. Is the patient 7 years of age or older?	
☐ Yes	□ No

Prescriber Signature

Date

EOC ID:

Copiktra-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start	date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested	medication:	
 Chronic lymphocytic leukemia/small lymphocytic lymphon Follicular lymphoma, relapsed or refractory Other 	na (CLL/SLL), relapsed or refractory	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Has the patient been treated with at least 2 prior therapies?		
	□ No	
Q6. Is the requested medication being prescribed by (or in consultation with) an oncologist or hematologist?		
	□ No	
Q7. Is the patient 18 years of age or older?		
☐ Yes	🗌 No	

EOC ID:

Copiktra-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Prescriber Signature

Date

EOC ID:

Corlanor-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Chronic heart failure (stable, symptomatic)	Other	
Q4. If the patient's diagnosis is OTHER, please specify be	low:	
Q5. Is the patient's left ventricular ejection fraction (LVEF) 35	% or less?	
☐ Yes	□ No	
Q6. Is the patient in sinus rhythm with resting heart rate of 70 beats per minute or more?		
☐ Yes	□ No	
Q7. Is the patient on maximally tolerated doses of beta blockers OR has a contraindication to beta blocker use?		
☐ Yes	□ No	
Q8. Is the patient 18 years of age or older?		

EOC ID:

Corlanor-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
☐ Yes	□ No	
Q9. Does the patient have any of the following (please select all that apply)?		
Decompensated acute heart failure		
Hypotension (i.e. blood pressure less than 90/50 mmHg)		
Sick sinus syndrome, sinoatrial block, or 3rd degree AV block (unless a functioning demand pacemaker is		
present)		
Bradycardia (i.e. resting heart rate is less than 60 beats per minute prior to treatment)		
□ None of the above		

Prescriber Signature

Date

EOC ID:

Cosentyx-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or co	ntinuing therapy?			
Initial therapy	Initial therapy Continuing therapy			
Q2. For CONTINUING THERA	PY, please provide the start date	(MM/YY):		
Q3. For CONTINUING THEAR Cosentyx therapy?	PY, is there documentation that t	he patient has had a positive clinical response to		
☐ Yes	C] No		
Q4. Please indicate the patient's diagnosis for the requested medication:				
Ankylosing spondylitis (act	Ankylosing spondylitis (active)			
Plaque psoriasis (moderate	e to severe)			
Psoriatic arthritis (active)				
Other				
Q5. If the patient's diagnosis is OTHER, please specify below:				
Q6. Has the patient tried and failed (or has a contraindication or intolerance) to any of the following (please select all that apply)?				
	Humira	□ None of the above		

EOC ID:

Cosentyx-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Q7. Will the patient be using Cosentyx in combination with any of the following (please select all that apply)?			
A biologic DMARD (such as Enbrel, Humira, Cimzia, or Simponi)			
A Janus kinase inhibitor (such as Xeljanz)			
None of the above			
Q8. For PSORIATIC ARTHRITIS OR PLAQUE PSORIASIS, will the patient be using Cosentyx in combination with a phosphodiesterase 4 (PDE4) inhibitor (such as Otezla)?			
Yes No			
Q9. Please indicate the prescriber's specialty below:			
Dermatologist Rheumatol	ogist None of the above		

Prescriber Signature

Date

EOC ID:

Cotellic-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please indicate the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Melanoma (unresectable or metastatic)	☐ Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Does the patient have BRAF V600E or V600K mutation?		
	□ No	
Q6. Will the requested medication be used in combination with vemurafenib (Zelboraf)?		
	□ No	

EOC ID:

Cotellic-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Cystaran-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
☐ Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested medication:		
☐ Cystinosis	Other	
Q4. If the patient's diagnosis is OTHER, please specify belo	ow:	
Q5. Does the patient have corneal crystal accumulation?		
☐ Yes	□ No	

EOC ID:

Cystaran-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
Prescriber Signature	Date

EOC ID:

Daurismo-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (i	if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested medication:		
Acute myeloid leukemia (newly diagnosed)	Other	
Q4. If the patient's diagnosis is OTHER, please specify bel	ow:	
Q5. Does the patient have comorbidities that preclude the use	e of intensive induction chemotherapy?	
☐ Yes	□ No	
Q6. Will Daurismo be used in combination with low-dose cytarabine?		
☐ Yes	□ No	
Q7. Is the patient 75 years of age or older?		
	□ No	
Q8. Is the medication being prescribed by (or in consultation with) an oncologist or hematologist?		

EOC ID:

Daurismo-1 Medicare

Phone: 800-361-4542

Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
☐ Yes	□ No	

Prescriber Signature

Date

EOC ID:

Diclofenac Topical-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicabl	e):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing th	erapy?
Initial therapy	Continuing therapy
Q2. For CONTINUING THERAPY, please	indicate the start date (MM/YY).
Q3. Please indicate the patient's diagnosis	or the requested medication:
Actinic keratosis	Other
Q4. If the patient's diagnosis is OTHER, I	please specify below:

EOC ID:

Diclofenac Topical-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
---------------	------------------

hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

EOC ID:

Dronabinol-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please specify the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested r	nedication: *	
Anorexia associated with weight loss in a patient with AID	S	
 Nausea and vomiting (N/V) associated with cancer chemo Other 	otherapy	
Q4. FOR ANOREXIA: Has the patient had an involuntary weight loss of greater than 10% of pre-illness baseline body weight OR a body mass index (BMI) less than 20kg/m2 in the absence of a concurrent illness or medical condition other than HIV that may cause weight loss?		
☐ Yes	No	
Q5. FOR ANOREXIA: Has the patient failed to respond to a 30-day trial of megestrol (Megace)?		
☐ Yes	□ No	
Q6. IF CONTINUING THERAPY FOR ANOREXIA: Has the patient shown a positive response to therapy by maintaining or increasing their initial weight and/or muscle mass?		
☐ Yes	No	

EOC ID:

Dronabinol-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Q7. FOR N/V: Is the patient currently receiving a chemotherapy or radiation regimen?		
Yes	□ No	
Q8. FOR N/V: Is oral drug being used as a full therapeutic replacement for an intravenous anti-emetic drug as part of a cancer chemotherapeutic regimen administered within 48 hours of chemotherapy?		
Yes	□ No	
Q9. FOR N/V: Has the patient had a full trial and failure through at least one cycle of chemotherapy with IV ondansetron?		
Yes	□ No	
Q10. FOR N/V: Has the patient tried and failed at least one of the following oral anti-emetic agents: metoclopramide, promethazine, prochlorperazine, meclizine, trimethobenzamide, or oral 5-HT3 receptor antagonists?		
Yes	No	
Q11. IF CONTINUING THERAPY FOR N/V: Has the patient shown a positive response to therapy by reduced incidence of emesis and/or nausea?		
Yes	□ No	
Q12. If the patient's diagnosis is OTHER, please speci	fy below:	

Prescriber Signature

Date

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

EOC ID:

Enbrel-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	_
Initial therapy	Continuing therapy
Q2. For CONTINUING THERAPY, please provide the start	date (MM/YY):
Q3. Please indicate the patient's diagnosis for the requested m	nedication:
Ankylosing spondylitis	
Plaque psoriasis (moderate to severe)	
Polyarticular juvenile idiopathic arthritis (moderate to seven	e)
Psoriatic arthritis Phouracted arthritis (moderate to severe)	
 Rheumatoid arthritis (moderate to severe) Other 	
Q4. If the patient's diagnosis is OTHER, please specify belo	w:
Q5. Do any of the following apply to this patient (please select	all that apply)?
☐ The patient has an active serious infection (including tub	perculosis)
☐ The patient will be using Enbrel with another biologic dis	ease-modifying anti-rheumatic drug (DMARD)
The patient will be using Enbrel with potent immunosup	pressant (such as azathioprine or cyclosporine)
None of the above	

EOC ID:

Enbrel-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Q6. Has the patient tried and failed (or has a contraindication or intolerance to) one or more of the following (please select all that apply)?		
 Methotrexate (MTX) Non-biologic disease modifying anti-rheumatic drugs (DMARDs) for at least 3 consecutive months Non-steroidal anti-inflammatory drugs (NSAIDs) Conventional therapy with phototherapy (including but not limited to Ultraviolet A with a psoralen [PUVA] and/or retinoids [RePUVA]) for at least one continuous month Conventional therapy with oral systemic treatments (such as methotrexate, cyclosporine, acitretin, sulfasalazine) for at least 3 consecutive months None of the above 		
Q7. For PLAQUE PSORIASIS, does the patient's disease affect more than 5% of the body surface area (BSA) or affect crucial body areas such as the hands, feet, face, or genitals?		
Yes	□ No	
 Q8. Please indicate the patient's age below: Under 2 years 2-3 years 4-17 years 18 years or older 		

Prescriber Signature

Date

EOC ID:

Endari-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please p	provide the start date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Sickle cell disease (acute)	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Has the patient tried and failed (or has an intolerance or o	contraindication to) hydroxyurea?	
☐ Yes	□ No	
Q6. Is the patient 5 years of age or older?		
	□ No	

EOC ID:

Endari-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Entresto-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
☐ Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the sta	rt date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Heart failure	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Please select the patient's New York Heart Association (NYHA) Class of heart failure: NYHA Class I NYHA Class II NYHA Class III NYHA Class IV		
Q6. Does the patient have any of the following EXCLUSIONS (please select all that apply)? Patient has history of angioedema related to previous ACE-inhibitor or ARB therapy Patient will be using Entresto concomitantly, or within 36 hours of an ACE-inhibitor Entresto will be used concomitantly with aliskiren (Tekturna) in a diabetic patient None of the above		

EOC ID:

Entresto-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
Q7. Is the patient at least 18 years of age or older?	
☐ Yes	□ No

Prescriber Signature

Date

EOC ID:

Epidiolex-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
☐ Initial therapy	Continuing therapy
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the request	ed medication:
Severe myoclonic epilepsy in infancy	
Lennox-Gestaut syndrome (LGS)	
Other	
Q4. Is the patient 2 years of age or older?	
☐ Yes	□ No
Q5. If the patient's diagnosis is OTHER, please specify below:	
Q6. Is the requested medication being prescribed by (or in consultation with) a neurologist?	
	□ No

EOC ID:

Epidiolex-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Erleada-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy? Initial therapy Q2. For CONTINUING THERAPY, please provide the start date (MM/YY): Q3. Please indicate the patient's diagnosis for the requested metication: Prostate cancer (non-metastatic) Q4. If the patient's diagnosis is OTHER, please specify below: Q5. Is the patient's disease castration-resistant? Yes Q6. Is the patient 18 years of age or older? Yes Q7. Is the requested medication being prescribed by (or in consultation with) an oncologist or urologist? Yes Q8. Is the patient pregnant? Yes			
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY): Q3. Please indicate the patient's diagnosis for the requested medication: Prostate cancer (non-metastatic) Q4. If the patient's diagnosis is OTHER, please specify below: Q5. Is the patient's disease castration-resistant? Yes Q6. Is the patient 18 years of age or older? Yes Q7. Is the requested medication being prescribed by (or in consultation with) an oncologist or urologist? Q8. Is the patient pregnant?	Q1. Is this request for initial or continuing therapy?		
Q3. Please indicate the patient's diagnosis for the requested medication: Prostate cancer (non-metastatic) Q4. If the patient's diagnosis is OTHER, please specify below: Q5. Is the patient's disease castration-resistant? Yes No Q6. Is the patient 18 years of age or older? Yes Yes No Q7. Is the requested medication being prescribed by (or in consultation with) an oncologist or urologist? Yes Q8. Is the patient pregnant?	Initial therapy	Continuing therapy	
□ Prostate cancer (non-metastatic) □ Other Q4. If the patient's diagnosis is OTHER, please specify below: Q5. Is the patient's disease castration-resistant? □ Yes □ No Q6. Is the patient 18 years of age or older? □ Yes □ No Q7. Is the requested medication being prescribed by (or in consultation with) an oncologist or urologist? □ Yes □ No Q8. Is the patient pregnant?	Q2. For CONTINUING THERAPY, please provide the start	date (MM/YY):	
□ Prostate cancer (non-metastatic) □ Other Q4. If the patient's diagnosis is OTHER, please specify below: Q5. Is the patient's disease castration-resistant? □ Yes □ No Q6. Is the patient 18 years of age or older? □ Yes □ No Q7. Is the requested medication being prescribed by (or in consultation with) an oncologist or urologist? □ Yes □ No Q8. Is the patient pregnant?			
Q4. If the patient's diagnosis is OTHER, please specify below: Q5. Is the patient's disease castration-resistant? Yes No Q6. Is the patient 18 years of age or older? Yes Yes No Q7. Is the requested medication being prescribed by (or in consultation with) an oncologist or urologist? Yes Q8. Is the patient pregnant?	Q3. Please indicate the patient's diagnosis for the requested r	nedication:	
Q5. Is the patient's disease castration-resistant? Yes No Q6. Is the patient 18 years of age or older? Yes No Q7. Is the requested medication being prescribed by (or in consultation with) an oncologist or urologist? Yes No Q8. Is the patient pregnant?	Prostate cancer (non-metastatic)	Other	
Yes No Q6. Is the patient 18 years of age or older? Yes No Q7. Is the requested medication being prescribed by (or in consultation with) an oncologist or urologist? Yes No Q8. Is the patient pregnant?	Q4. If the patient's diagnosis is OTHER, please specify below:		
Q6. Is the patient 18 years of age or older? Yes Q7. Is the requested medication being prescribed by (or in consultation with) an oncologist or urologist? Yes No Q8. Is the patient pregnant?	Q5. Is the patient's disease castration-resistant?		
Yes No Q7. Is the requested medication being prescribed by (or in consultation with) an oncologist or urologist? Yes No Q8. Is the patient pregnant?	☐ Yes	□ No	
Q7. Is the requested medication being prescribed by (or in consultation with) an oncologist or urologist?	Q6. Is the patient 18 years of age or older?		
Yes No Q8. Is the patient pregnant?	☐ Yes	□ No	
Q8. Is the patient pregnant?	Q7. Is the requested medication being prescribed by (or in col	nsultation with) an oncologist or urologist?	
	☐ Yes	□ No	
Yes	Q8. Is the patient pregnant?		
	☐ Yes		

EOC ID:

Erleada-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:

N/A - The patient is not a female or not of child-bearing potential

Prescriber Signature

🗌 No

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Date

EOC ID:

ESA-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial therapy or continuing therapy? *		
☐ Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please specify the start	date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested r	nedication: *	
Anemia associated with chronic kidney disease (CKD)		
Anemia associated with myelosuppressive chemotherapy		
Anemia associated with zidovudine therapy in a patient with HIV infection		
 Reduction of blood transfusions in a patient undergoing elective, non-cardiac, non-vascular surgery Other 		
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the patient's pre-treatment hemoglobin level less than 1	10 g/dL?	
☐ Yes	□ No	
Q6. Will there be a dose reduction or interruption if the hemoglobin level exceeds one of the following: 10 g/dL (adult CKD not on dialysis, or cancer); 11 g/dL (CKD on dialysis); or 12 g/dL (pediatric CKD)?		
	□ No	

EOC ID:

ESA-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Prescriber Signature

Date

EOC ID:

Esbriet-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please specify the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Idiopathic pulmonary fibrosis (IPF)	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the prescriber a pulmonologist?		
	□ No	
Q6. Will the patient's hepatic function and liver function tests (LFTs) be monitored?		
☐ Yes	□ No	

EOC ID:

Esbriet-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Farydak-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Multiple myeloma	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the patient 18 years of age or older?		
	□ No	
Q6. Will Farydak be used in combination with bortezomib (Velcade) and dexamethasone?		
☐ Yes	□ No	
Q7. Has the patient received at least two (2) prior regimens, including bortezomib (Velcade) and an immunomodulatory agent [eg, Revlimid (lenalidomide), Thalomid (thalidomide)]?		
☐ Yes	□ No	
Q8. Is the requested medication being prescribed by (or in consultation with) an oncologist/hematologist?		

EOC ID:

Farydak-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
☐ Yes	□ No

Prescriber Signature

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Date

EOC ID:

Fentanyl Oral-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:	Office Contact:	
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?			
☐ Initial therapy	Continuing therapy		
Q2. For CONTINUING THERAPY, please specify the start date (MM/YY):			
Q3. Please indicate the patient's diagnosis for the requested r	nedication:		
Breakthrough cancer pain (in an opioid-tolerant patient)	☐ Other		
Q4. If the patient's diagnosis is OTHER, please specify below:			
Q5. Is the patient 16 years of age or older?			
☐ Yes	□ No		
Q6. If the patient is taking any strong or moderate cytocyrome P450 (CYP450) 3A4 inhibitors, (such as aprepitant, clarithromycin, diltiazem, erythromycin, fosamprenavir, fluconazole, itraconazole, ketoconazole, nefazodone, nelfinavir, ritonavir, verapamil) will they be monitored or have dosing adjustments made if necessary?			
□ N/A - Patient is not taking any strong CYP450 3A4 inhibito	ors		
Q7. The plan has the following quantity limits in place: 120 lozenges per 30 days. Will the patient require a quantity			

EOC ID:

Fentanyl Oral-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
greater than this?		
☐ Yes	□ No	
Q8. If the patient requires a quantity greater than specified above, please provide rationale for a quantity limit exception:		

Prescriber Signature

Date

EOC ID:

Filgrastim-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:	Office Contact:	
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy? Initial therapy Continuing therapy Q2. For continuing therapy, please specify start date (MM/YY): Q3. Please indicate the patient's diagnosis for the requested medication below: * Febrile neutropenia, In non-myeloid malignancies following myelosuppressive chemotherapy; Prophylaxis Febrile neutropenia, In non-myeloid malignancies, in patients undergoing myeloablative chemotherapy followed by marrow transplantation; Prophylaxis Febrile neutropenia, In patients with acute myeloid leukemia receiving chemotherapy; Prophylaxis Harvesting of peripheral blood stem cells Hematopoietic subsyndrome of acute radiation syndrome Neutropenic disorder, chronic (Severe), Symptomatic Other Q4. For patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, please select if any of the following apply to this patient: Patient experienced febrile neutropenia with a prior chemotherapy cycle The patient is at high risk (greater than 20%) or intermediate risk (10-20%) for developing febrile neutropenia Patient is at low risk (less than 10%) but is at significant risk for serious medical consequences due to febrile neutropenia and the intent of chemotherapy is to prolong survival or cure the disease Patient is at low risk (less than 10%) but is at significant risk for serious medical consequences due to febrile neutropenia in patients who have received prophylaxis with Neupogen or Zarxio <th></th> <th></th>			
Q2. For continuing therapy, please specify start date (MM/YY): Q3. Please indicate the patient's diagnosis for the requested medication below: * Febrile neutropenia, In non-myeloid malignancies following myelosuppressive chemotherapy; Prophylaxis Febrile neutropenia, In non-myeloid malignancies, in patients undergoing myeloablative chemotherapy followed by marrow transplantation; Prophylaxis Febrile neutropenia, In patients with acute myeloid leukemia receiving chemotherapy; Prophylaxis Harvesting of peripheral blood stem cells Hematopoietic subsyndrome of acute radiation syndrome Neutropenic disorder, chronic (Severe), Symptomatic Other Q4. For patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, please select if any of the following apply to this patient: Patient experienced febrile neutropenia with a prior chemotherapy cycle The patient is at high risk (greater than 20%) or intermediate risk (10-20%) for developing febrile neutropenia Patient is at low risk (less than 10%) but is at significant risk for serious medical consequences due to febrile neutropenia and the intent of chemotherapy is to prolong survival or cure the disease	Q1. Is this request for initial or continuing therapy?		
Q3. Please indicate the patient's diagnosis for the requested medication below: * ☐ Febrile neutropenia, In non-myeloid malignancies following myelosuppressive chemotherapy; Prophylaxis ☐ Febrile neutropenia, In non-myeloid malignancies, in patients undergoing myeloablative chemotherapy followed by marrow transplantation; Prophylaxis ☐ Febrile neutropenia, In patients with acute myeloid leukemia receiving chemotherapy; Prophylaxis ☐ Harvesting of peripheral blood stem cells ☐ Hematopoietic subsyndrome of acute radiation syndrome ☐ Neutropenic disorder, chronic (Severe), Symptomatic ☐ Other Q4. For patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, please select if any of the following apply to this patient: ☐ Patient experienced febrile neutropenia with a prior chemotherapy cycle ☐ The patient is at high risk (greater than 20%) or intermediate risk (10-20%) for developing febrile neutropenia ☐ Patient is at low risk (less than 10%) but is at significant risk for serious medical consequences due to febrile neutropenia and the intent of chemotherapy is to prolong survival or cure the disease	☐ Initial therapy	Continuing therapy	
 Febrile neutropenia, In non-myeloid malignancies following myelosuppressive chemotherapy; Prophylaxis Febrile neutropenia, In non-myeloid malignancies, in patients undergoing myeloablative chemotherapy followed by marrow transplantation; Prophylaxis Febrile neutropenia, In patients with acute myeloid leukemia receiving chemotherapy; Prophylaxis Harvesting of peripheral blood stem cells Hematopoietic subsyndrome of acute radiation syndrome Neutropenic disorder, chronic (Severe), Symptomatic Other Q4. For patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, please select if any of the following apply to this patient: Patient experienced febrile neutropenia with a prior chemotherapy cycle The patient is at high risk (greater than 20%) or intermediate risk (10-20%) for developing febrile neutropenia Patient is at low risk (less than 10%) but is at significant risk for serious medical consequences due to febrile neutropenia survival or cure the disease 	Q2. For continuing therapy, please specify start date (MM/YY):		
 Febrile neutropenia, In non-myeloid malignancies, in patients undergoing myeloablative chemotherapy followed by marrow transplantation; Prophylaxis Febrile neutropenia, In patients with acute myeloid leukemia receiving chemotherapy; Prophylaxis Harvesting of peripheral blood stem cells Hematopoietic subsyndrome of acute radiation syndrome Neutropenic disorder, chronic (Severe), Symptomatic Other Q4. For patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, please select if any of the following apply to this patient: Patient experienced febrile neutropenia with a prior chemotherapy cycle The patient is at high risk (greater than 20%) or intermediate risk (10-20%) for developing febrile neutropenia Patient is at low risk (less than 10%) but is at significant risk for serious medical consequences due to febrile neutropenia and the intent of chemotherapy is to prolong survival or cure the disease 	Q3. Please indicate the patient's diagnosis for the requested medication below: *		
 marrow transplantation; Prophylaxis Febrile neutropenia, In patients with acute myeloid leukemia receiving chemotherapy; Prophylaxis Harvesting of peripheral blood stem cells Hematopoietic subsyndrome of acute radiation syndrome Neutropenic disorder, chronic (Severe), Symptomatic Other Q4. For patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, please select if any of the following apply to this patient: Patient experienced febrile neutropenia with a prior chemotherapy cycle The patient is at high risk (greater than 20%) or intermediate risk (10-20%) for developing febrile neutropenia Patient is at low risk (less than 10%) but is at significant risk for serious medical consequences due to febrile neutropenia and the intent of chemotherapy is to prolong survival or cure the disease 	E Febrile neutropenia, In non-myeloid malignancies following myelosuppressive chemotherapy; Prophylaxis		
 Harvesting of peripheral blood stem cells Hematopoietic subsyndrome of acute radiation syndrome Neutropenic disorder, chronic (Severe), Symptomatic Other Q4. For patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, please select if any of the following apply to this patient: Patient experienced febrile neutropenia with a prior chemotherapy cycle The patient is at high risk (greater than 20%) or intermediate risk (10-20%) for developing febrile neutropenia Patient is at low risk (less than 10%) but is at significant risk for serious medical consequences due to febrile neutropenia and the intent of chemotherapy is to prolong survival or cure the disease 			
 Hematopoietic subsyndrome of acute radiation syndrome Neutropenic disorder, chronic (Severe), Symptomatic Other Q4. For patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, please select if any of the following apply to this patient: Patient experienced febrile neutropenia with a prior chemotherapy cycle The patient is at high risk (greater than 20%) or intermediate risk (10-20%) for developing febrile neutropenia Patient is at low risk (less than 10%) but is at significant risk for serious medical consequences due to febrile neutropenia and the intent of chemotherapy is to prolong survival or cure the disease 	E Febrile neutropenia, In patients with acute myeloid leukemia receiving chemotherapy; Prophylaxis		
 Neutropenic disorder, chronic (Severe), Symptomatic Other Q4. For patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, please select if any of the following apply to this patient: Patient experienced febrile neutropenia with a prior chemotherapy cycle The patient is at high risk (greater than 20%) or intermediate risk (10-20%) for developing febrile neutropenia Patient is at low risk (less than 10%) but is at significant risk for serious medical consequences due to febrile neutropenia and the intent of chemotherapy is to prolong survival or cure the disease 	Harvesting of peripheral blood stem cells		
 Other Q4. For patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, please select if any of the following apply to this patient: Patient experienced febrile neutropenia with a prior chemotherapy cycle The patient is at high risk (greater than 20%) or intermediate risk (10-20%) for developing febrile neutropenia Patient is at low risk (less than 10%) but is at significant risk for serious medical consequences due to febrile neutropenia and the intent of chemotherapy is to prolong survival or cure the disease 	Hematopoietic subsyndrome of acute radiation syndrome		
Q4. For patients with non-myeloid malignancies receiving myelosuppressive chemotherapy, please select if any of the following apply to this patient:			
following apply to this patient: Patient experienced febrile neutropenia with a prior chemotherapy cycle The patient is at high risk (greater than 20%) or intermediate risk (10-20%) for developing febrile neutropenia Patient is at low risk (less than 10%) but is at significant risk for serious medical consequences due to febrile neutropenia and the intent of chemotherapy is to prolong survival or cure the disease			
 The patient is at high risk (greater than 20%) or intermediate risk (10-20%) for developing febrile neutropenia Patient is at low risk (less than 10%) but is at significant risk for serious medical consequences due to febrile neutropenia and the intent of chemotherapy is to prolong survival or cure the disease 			
Patient is at low risk (less than 10%) but is at significant risk for serious medical consequences due to febrile neutropenia and the intent of chemotherapy is to prolong survival or cure the disease	Patient experienced febrile neutropenia with a prior chemotherapy cycle		
neutropenia and the intent of chemotherapy is to prolong survival or cure the disease	The patient is at high risk (greater than 20%) or inte	rmediate risk (10-20%) for developing febrile neutropenia	
☐ For the treatment of febrile neutropenia in patients who have received prophylaxis with Neupogen or Zarxio		•	
	For the treatment of febrile neutropenia in patients v	vho have received prophylaxis with Neupogen or Zarxio	

EOC ID:

Filgrastim-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
(or Leukine) OR in patients at risk for infection-related complications		
Q5. If the patient's diagnosis is OTHER, please specify below:		
Q6. Are the patient's complete blood count and platelet count being monitored at baseline, and regularly thereafter?		
☐ Yes	□ No	
Q7. Please indicate if any of the following apply to this patient (select all that apply):		
 Administration within 24 hours preceding or following chemotherapy or radiotherapy E. coli hypersensitivity 		
For prophylaxis of febrile neutropenia: use to increase the chemotherapy dose intensity or dose schedule beyond established regimens		
Treatment of febrile neutropenia, when patient receives Neulasta during the current chemotherapy cycle None of the above		
1		

Prescriber Signature

Date

EOC ID:

Firdapse-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the star	t date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested medication:		
Lambert-Eaton myasthenic syndrome (LEMS)	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the patient 18 years of age or older?		
☐ Yes	□ No	
Q6. Does the patient have a history of seizures?		
☐ Yes	□ No	

Prescriber Signature

Date

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are

EOC ID:

Firdapse-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
---------------	------------------

hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

EOC ID:

Galafold-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please indicate the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested medication:		
E Fabry disease	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Does the patient have an amenable galactosidase alpha gene (GLA) mutation?		
☐ Yes	□ No	
Q6. Is the patient 18 years of age or older?		
	□ No	

EOC ID:

Galafold-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Gilotrif-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
☐ Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provid	e the start date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the r	equested medication:	
Non-small cell lung cancer (NSCLC), metast	tatic	
 Non-small cell lung cancer (NSCLC), metasta Other 	atic squamous (previously treated)	
Q4. Has the patient's disease progressed following platinum-based chemotherapy?		
☐ Yes	□ No	
Q5. If the patient's diagnosis is OTHER, please specify below:		
Q6. Do the patient's tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test?		
☐ Yes	□ No	
Q7. Is the patient 18 years of age or older?		
☐ Yes	□ No	

EOC ID:

Gilotrif-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Q8. Is the requested medication being prescribed by (or in consultation with) an oncologist?		
Yes	□ No	

Prescriber Signature

Date

EOC ID:

Gocovri-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing	therapy?		
Initial therapy	Continuing therapy		
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):			
Q3. For CONTINUING THERAPY, has the patient experienced a positive clinical response to Gocovri (such as decreased "off" periods, or decreased "on" time with troublesome dyskinesia)?			
☐ Yes	□ No		
Q4. Please indicate the patient's diagnosis	s for the requested medication:		
Parkinson disease	Other		
Q5. If the patient's diagnosis is OTHER, please specify below:			
Q6. Please check all that apply to this pati	ent:		
Patient is experiencing dyskinesia			
Patient is receiving levodopa based therapy			
Patient has tried and failed amantad	dine immediate release		
None of the above			
Q7. Does the patient have end stage renal disease (ESRD) (CrCl below 15 mL/min/m2)?			

EOC ID:

Gocovri-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
☐ Yes	□ No	
Q8. Is the requested medication being prescribed by (or in consultation with) a neurologist?		
☐ Yes	□ No	

Prescriber Signature

Date

EOC ID:

Growth Hormone-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?			
Initial therapy	Continuing therapy		
Q2. For CONTINUING THERAPY, please specify the start date (MM/YY):			
Q3. For CONTINUING THERAPY (ADULT PATIENTS), p Patient has seen clinical improvement IGF-1 will be monitored None of the above	please select all that apply:		
Q4. Please indicate the patient's diagnosis for the requested Growth failure in children Growth failure associated with chronic kidney disease (CKD) Growth failure associated with Noonan Syndrome Growth failure associated with Prader-Willi Syndrome Growth failure associated with short stature homeobox gene (SHOX) deficiency Growth failure or short stature associated with Turner Syndrome	d medication: Growth failure in a pediatric patient born small for gestational age (SGA) Growth Hormone Deficiency (GHD) in neonates with hypoglycemia Growth Hormone Deficiency (GHD) in pediatrics Growth Hormone Deficiency (GHD) in adults Holiopathic short stature Other		

EOC ID:

Growth Hormone-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Q5. For GROWTH FAILURE ASSOCIATED WITH CKD, please select all that apply:		
 Metabolic, endocrine, and nutritional abnormalities have been treated or stabilized The patient has not had a kidney transplant None of the above 		
Q6. For GROWTH FAILURE ASSOCIATED WITH TU confirmed by genetic testing?	RNER SYNDROME OR SHOX, has the diagnosis been	
Yes	□ No	
Q7. For GROWTH FAILURE IN A PATIENT BORN SH low birth weight or length for gestational age?	IORT FOR GESTATIONAL AGE (SGA), did the patient have a	
Yes	□ No	
 Q8. For GHD IN NEONATES WITH HYPOGLYCEMIA, please select all that apply: The patient has a randomly assessed growth hormone (GH) level less than 20 ng/mL Other causes of hypoglycemia have been ruled out Other treatments have been ineffective None of the above 		
 Q9. For PEDIATRIC GHD, please select all that apply: The patient has delayed bone age The patient does not have pituitary disease, an The patient has pituitary or CNS disorder, and I None of the above 		
and has low IGF-1	GHD-like symptoms	
Q11. For IDIOPATHIC SHORT STATUTE, has pediatric GHD been ruled out with at least one (1) stimulation test?		
Yes	□ No	
Q12. If the patient's diagnosis is OTHER, please speci	fy below:	
Q13. Please select the prescriber's specialty below:		

EOC ID:

Growth Hormone-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
 Gastroenterologist Infectious disease (ID) specialist Nutritional support specialist Pediatric nephrologist None of the above 		
Q14. Please indicate the patient's age below: Under 2 years of age 2-3 years of age 3 years of age or older		
Q15. For PEDIATRIC PATIENTS, please select all that apply:		

Prescriber Signature

Date

EOC ID:

Hepatitis C-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested r	nedication:	
Chronic Hepatitis C	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the patient 18 years of age or older?		
☐ Yes	□ No	
Q6. Please indicate the prescriber's specialty below:		
Gastroenterologist		
Hepatologist		
Infectious Disease Specialist		
Other		
Q7. If the prescriber's specialty is OTHER, please specify:		

EOC ID:

Hepatitis C-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Q8. Please provide the patient's genotype confirmed by HCV RNA level within the last 6 months (must submit documentation):		
Q9. Please provide the patient's subtype (must submit documentation):		
Q10. Please provide the patient's HCV RNA (viral load) level (must submit documentation):		
Q11. Is the patient post-transplant?		
Yes	□ No	
Q12. What is the patient's cirrhosis status?		
Q13. What is the patient's prior treatment history?		
Q14. What is the patient's planned duration of treatment?		
Q15. Has the prescriber documented the following within 12 weeks of initiating therapy: 1) CBC w Platelets, 2) AST/ALT, 3) Total Bilirubin, 4) Serum Albumin, 5) PT/INR, 6) Serum Creatinine, and 7) GFR?		
☐ Yes	□ No	
Q16. For Vosevi: Has the patient previously tried and faile Yes No N/A - The request is for Mavyret	ed (or had a contraindication or intolerance to) Mavyret?	

Prescriber Signature

Date

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are

EOC ID:

Hepatitis C-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
---------------	------------------

hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

EOC ID:

Hetlioz-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:	Office Contact:	
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested medication:		
Non-24-hour-sleep-wake disorder (Non-24)	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Does the patient have documented blindness?		
☐ Yes	□ No	
Q6. Is the patient 18 years of age or older?		
☐ Yes	□ No	

EOC ID:

Hetlioz-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

HRM ADHD-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:	Office Contact:	
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial		
Q2. For continuing therapy, please specify start date (MM/YY):		
Q3. Is the patient greater than or equal to 65 years of age?		
☐ Yes	□ No	
Q4. Please indicate the diagnosis for which the requested medication is being prescribed:		
Attention deficit hyperactivity disorder (ADHD)		
Other		
Q5. If the diagnosis is OTHER, please specify.		

EOC ID:

HRM ADHD-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Date

Prescriber Signature

EOC ID:

HRM Analgesics-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:	Office Contact:	
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For continuing therapy, please specify start date (MM/)	Y):	
Q3. Is the patient greater than or equal to 65 years of age?		
☐ Yes	□ No	
Q4. Please indicate the diagnosis for which the requested me	dication is being prescribed:	
Tension or muscle contraction headache		
Acute Pain		
Osteoarthritis		
Gout		
Ankylosing Spondylitis		
Rheumatoid Arthritis		
Other		
Q5. If the diagnosis is OTHER, please specify below:		

EOC ID:

HRM Analgesics-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

HRM Anti-Arrhythmics-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?			
Q2. For continuing therapy, please specify start date (MM/YY):			
Q3. Please indicate the patient's diagnosis below:			
Uentricular arrhythmia	□ Other		
Q4. If the diagnosis is OTHER, please specify.			
Q5. Is the patient greater than or equal to 65 years of age?			
☐ Yes	□ No		
Q6. FOR PRESCRIBER INFORMATION ONLY: For patients greater than or equal to 65 years, coverage determination is approved for FDA-approved indications not otherwise excluded from Part D. Disopyramide: rate control preferred for atrial fibrillation.			

EOC ID:

HRM Anti-Arrhythmics-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

HRM Antidepressants-8 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
	Continuing
Q2. For continuing therapy, please specify start date (MM/	(Y):
Q3. Please indicate which medication is being requested:	
Clomipramine (Anafranil)	
Imipramine HCI (Tofranil)	
Imipramine Pamoate (Tofranil-PM)	
Trimipramine (Surmontil)	
None of the above	
Other	
Q4. If medication is Other, please specify:	
Q5. Please provide the patient's diagnosis below:	
Obsessive-Compulsive Disorder	

EOC ID:

HRM Antidepressants-8 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Enuresis Other		
Q6. If the diagnosis is OTHER, please specify.		
Q7. Is the patient greater than or equal to 65 years of age?		
☐ Yes	□ No	

Prescriber Signature

Date

EOC ID:

HRM Antiemetics-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:		
Primary Phone:	Specialty/facility name	(if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please indicate Start Date (MM/YY):		
Q3. Please indicate which medication is requested:		
Hydroxyzine		
Other		
Q4. If medication is Other, Please specify:		
Q5. Is the patient 65 years of age or older?		
	□ No	
Q6. Please indicate the patient's diagnosis for the requested medication:		
Pruritus/Allergic conditions		
Sedation		
Anxiety/tension		
☐ Nausea/Vomiting		

EOC ID:

HRM Antiemetics-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
 Motion sickness Adjunct to analgesia Other 		
Q7. If the patient's diagnosis is OTHER, please specify below:		
Q8. FOR PRESCRIBER INFORMATION ONLY: Formulary non-HRM alternatives are as follows: Nausea/Vomiting: granisetron, ondansetron. Allergic Reactions: levocetirizine		

Prescriber Signature

Date

EOC ID:

HRM Antihistamines-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applical	ble):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For continuing therapy, please specify start date (MM/	YY):	
Q3. Please indicate the patient's diagnosis below:		
Allergic/vasomotor rhinitis		
Allergic conjunctivitis		
🗌 Urticaria		
Hypersensitivity reaction		
Other		
Q4. If the diagnosis is OTHER, please specify below:		
Q5. Is the patient greater than or equal to 65 years of age?		
	□ No	

EOC ID:

HRM Antihistamines-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

HRM Antiparkinson Agents-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
Initial therapy	Continuing therapy
Q2. For continuing therapy, please specify start date (MM/Y	Y):
Q3. Please indicate the patient's diagnosis below:	
Parkinson's disease	
Extrapyramidal disease - Medication-induced movemer	it disorder
Other	
Q4. If the diagnosis is OTHER, please specify below:	
OF is the notiont greater then as equal to CF years of ano?	
Q5. Is the patient greater than or equal to 65 years of age?	
	No

EOC ID:

HRM Antiparkinson Agents-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Date

Prescriber Signature

EOC ID:

HRM Antipsychotics-6 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial	Continuing	
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested medication:		
Schizophrenia	☐ Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the patient greater than or equal to 65 years of age?		
☐ Yes	□ No	

EOC ID:

HRM Antipsychotics-6 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
Prescriber Signature	Date

EOC ID:

HRM Barbiturates-5 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
☐ Initial therapy	Continuing therapy
Q2. For continuing therapy, please specify start date (MM/Y	Ύ):
Q3. Please indicate the diagnosis for which the requested me	dication is being prescribed:
Seizure Disorder	
Other	
Q4. If the diagnosis is OTHER, please specify below:	
Q5. Is the patient greater than or equal to 65 years of age?	
☐ Yes	□ No
Q6. FOR PRESCRIBER INFORMATION ONLY: Formulary non-HRM alternatives are as follows: a) ANXIETY: (citalopram, escitalopram, fluvoxamine, sertraline, duloxetine, venlafaxine, buspirone) b) INSOMNIA: low dose trazodone.	

EOC ID:

HRM Barbiturates-5 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:

Prescriber Signature

Date

EOC ID:

HRM Dementia Agents-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

O1 to this request for initial or continuing therapy?	
Q1. Is this request for initial or continuing therapy?	
Initial therapy	Continuing therapy
Q2. If the request is for CONTINUING THERAPY, please p	provide the start date (MM/YY):
Q3. Please indicate the patient's diagnosis for the requested	medication:
Dementia (progressive, Alzheimer's, or senile onset)	Other
Q4. If diagnosis is OTHER, please specify below:	
Q5. Is the patient 65 years of age or older?	
	□ No
Q6. FOR PRESCRIBER INFORMATION ONLY: Formulary non-HRM alternatives are as follows: Antidementia: donepezil, galantamine, memantine ER, rivastigmine capsule, rivastigmine patch.	

EOC ID:

HRM Dementia Agents-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

HRM Estrogens-7 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For continuing therapy, please specify start of	late (MM/YY):	
Q3. Please indicate the diagnosis for which this me	dication is being prescribed:	
Abnormal vasomotor function (Moderate to Sev	ere) - Menopause	
Atrophic vulva/vagina (Moderate to Severe) - M	enopause	
Prevention of postmenopausal osteoporosis		
Decreased estrogen level, Secondary to hypogonadism, castration, or primary ovarian failure		
Breast cancer, Metastatic; for palliation only		
Prostate cancer, Advanced, Androgen-depende	ent; for palliation only	
Other		
Q4. If the patient's diagnosis is OTHER, please s	pecify below.	
Q5. Is the patient greater than or equal to 65 years	of age?	
☐ Yes	□ No	
Q6. FOR PRESCRIBER INFORMATION ONLY: For Premarin Cream and Estradiol Cream. Osteoporosi	ormulary non-HRM alternatives are as follows: Localized options: s: Alendronate and Risedronate.	

EOC ID:

HRM Estrogens-7 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Date

EOC ID:

HRM Muscle Relaxant-8 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested n	nedication:	
Acute Painful Musculoskeletal conditions		
Chronic Intermittent Painful Musculoskeletal conditions		
🗌 Fibromyalgia		
Restless Leg Syndrome		
Nocturnal Leg Cramps		
Other		
Q4. If the patient's diagnosis is OTHER, please specify:		
Q5. Is the patient greater than or equal to 65 years of age?		
Yes	□ No	

EOC ID:

HRM Muscle Relaxant-8 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

HRM Oncology-6 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
☐ Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please p	rovide the start date (MM/YY):	
Q3. Please indicate the diagnosis for which the requested me	dication is being prescribed: *	
Cachexia associated with AIDS		
Breast cancer, palliative treatment of advanced disease		
Endometrial carcinoma, palliative treatment of advanced disease		
Other		
Q4. If the diagnosis is OTHER, please specify below:		
Q5. Is the patient greater than or equal to 65 years of age?		
☐ Yes	□ No	
Q6. FOR PRESCRIBER INFORMATION ONLY: Formulary no	on-HRM alternatives for diagnosis of cachexia secondary	
to chronic illness are: dronabinol, oxandrolone.		

EOC ID:

HRM Oncology-6 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

HRM Platelet Inhibitors-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable	e):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
Initial therapy	Continuing therapy
Q2. For continuing therapy, please specify start date (MM/)	(Y):
Q3. Please indicate the patient's diagnosis below:	
 Heart valve replacement - Thromboembolic disorder; P Cerebrovascular accident; Prophylaxis Other 	rophylaxis
Q4. If the diagnosis is OTHER, please specify below:	
Q5. Is the patient greater than or equal to 65 years of age?	
	□ No
Q6. FOR PRESCRIBER INFORMATION ONLY: Formulary no Cilostazol, Clopidogrel.	on-HRM alternatives are as follows: Platelet Inhibitors:

EOC ID:

HRM Platelet Inhibitors-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

HRM Sedative Hypnotics-7 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
☐ Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please indicate Start Date (MM/YY):		
Q3. Please indicate the patient's diagnosis:		
Insomnia	☐ Other	
Q4. If the patient's diagnosis is OTHER, please specify belo	w:	
Q5. Is the patient greater than or equal to 65 years of age?		
☐ Yes	No	

EOC ID:

HRM Sedative Hypnotics-7 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
Prescriber Signature	Date

EOC ID:

Humira-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	Continuing therapy		
Q2. For continuing therapy, please specify the start date (MM/YY):			
Q3. Please indicate the patient's diagnosis for the requested	medication:		
 Ankylosing Spondylitis Crohn's Disease (moderate to severe) Hidradenitis suppurativa (moderate to severe) Non-infectious Uveitis (including intermediate, posterior, and panuveitis) Plaque psoriasis (chronic) 	 Polyarticular juvenile idiopathic arthritis (pJIA) (moderate to severe) Psoriatic arthritis Rheumatoid arthritis (moderate to severe) Ulcerative colitis (moderate to severe) Other 		
Q4. For PLAQUE PSORIASIS, does the patient's disease affect more than 5% of the body surface area (BSA) or affect crucial body areas such as the hands, feet, face, or genitals?			
☐ Yes	□ No		
Q5. If the patient's diagnosis is OTHER, please specify below:			
Q6. Has the patient tried and failed (or has a contraindication or intolerance to) any of the following (please select all that apply)?			

EOC ID:

Humira-1 Medicare

Phone: 800-361-4542

Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
 RA or pJIA - one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs) for at least 3 consecutive months PSORIATIC ARTHRITIS - methotrexate ANKYLOSING SPONDYLITIS - one or more non-steroidal anti-inflammatory drugs (NSAIDs) PLAQUE PSORIASIS - conventional therapy with phototherapy (such as UVA with a psoralen [PUVA] and/or retinoids [RePUVA]) for at least one continuous month PLAQUE PSORIASIS - conventional therapy with one or more oral systemic treatments (such as cyclosporine, acitretin, sulfasalazine, methotrexate, leflunomide, azathioprine) for at least 3 consecutive months 	 CROHN'S DISEASE - two or more corticosteroids or non-biologic DMARDs ULCERATIVE COLITIS - two or more corticosteroids, 5-ASA (such as mesalamine, sulfasalazine, balsalazide), or non-biologic DMARDs (azathioprine, cyclosporine, hydroxychloroquine, leflunomide, sulfasalazine) UVEITIS - one of the following: systemic or topical corticosteroids or ophthalmic antimuscarinics None of the above 	
 Q7. Please indicate the patient's age below: Under 2 years 2-5 years 6-11 years 12-17 years old 18 years or older 		
Q8. Does the patient have any active serious infections (including tuberculosis [TB])?		
☐ Yes	□ No	
Q9. Will the patient be using Humira in combination with a biologic disease-modifying anti-rheumatic drugs or potent immunosuppressant (such as azathioprine or cyclosporine)?		
☐ Yes	□ No	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are

EOC ID:

Humira-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
---------------	------------------

hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

EOC ID:

Ibrance-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please indicate the start	t date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested in	medication:	
Breast cancer, advanced or metastatic	Other	
Q4. If the patient's diagnosis is OTHER, please specify bel	DW:.	
Q5. Is the patient's disease hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- negative?		
☐ Yes	□ No	
Q6. Please indicate how the requested medication will be used:		
In combination with an aromatase inhibitor in a postmenopausal women or a man, as initial endocrine-based therapy		
 In combination with fulvestrant in a woman with disease None of the above 	e progression following endocrine therapy	
Q7. Is the patient 18 years of age or older?		

EOC ID:

Ibrance-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
☐ Yes	□ No
Q8. Is the medication prescribed by (or in consultation with) an oncologist?	
☐ Yes	□ No

Prescriber Signature

Date

EOC ID:

Iclusig-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or contin	uing therapy?		
Initial therapy		Continuing therapy	
Q2. If the request is for CONTINU	ING THERAPY, please provide	e the start date (MM/YY):	
Q3. Please indicate the patient's dia	gnosis for the requested medic	ation:	
Acute lymphoblastic leukemia, F	hiladelphia chromosome-positi	ive (Ph+ALL)	
Chronic myeloid leukemia (CML	Chronic myeloid leukemia (CML) (chronic, accelerated, or blast phase)		
Other			
Q4. If the patient's diagnosis is O	THER, please specify below:		
Q5. Please select if any of the following apply to this patient (please select all that apply):			
□ No other tyrosine kinase inhibitor therapy is indicated for this patient			
The patient is T315I-positive			
□ None of the above			
Q6. Please indicate the prescriber's specialty below:			
Hematologist	Oncologist	Other	
Q7. If the prescriber's specialty is OTHER, please specify below:			

EOC ID:

Iclusig-2 Medicare

Phone: 800-361-4542

Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Date

EOC ID:

Idhifa-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the star	t date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested medication:		
Acute myeloid leukemia (AML), relapsed/refractory	Other	
Q4. If the patient's diagnosis is OTHER, please specify be	low:	
Q5. Does the patient have an an isocitrate dehydrogenase 2	mutation as detected by an FDA approved test?	
	□ No	
Q6. Is the patient 18 years of age or older?		
☐ Yes	□ No	
Q7. Is the requested medication prescribed by (or in consultation with) a hematologist or oncologist?		
☐ Yes	□ No	

EOC ID:

Idhifa-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Inbrija-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start	: date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Parkinson's disease	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Will the requested medication be used concurrently with	carbidopa/levodopa?	
	□ No	
Q6. Has the patient tried and failed (or has contraindication to) one generic formulary alternative?		
	□ No	
Q7. Is the patient 18 years old or older?		
☐ Yes	□ No	
Q8. Do any of the following apply to this patient (please select all that apply)?		
The patient is currently taking a nonselective monoamine oxidase inhibitor (MAOI) (such as phenelzine or		

EOC ID:

Inbrija-1 Medicare

Phone: 800-361-4542

Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
tranylcypromine)	
□ None of the above	

Prescriber Signature

Date

EOC ID:

Imbruvica-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing	therapy?
Initial therapy	Continuing therapy
Q2. If the request is for CONTINUING	THERAPY, please provide the start date (MM/YY):
Q3. Please indicate the patient's diagnosi	is for the requested medication:
Chronic lymphocytic leukemia (CLL)	ents who have received at least 1 prior therapy) efractory (in patients who require systemic therapy and have received at least 1
Q4. If the patient's diagnosis is OTHEF	२, please specify below:

EOC ID:

Imbruvica-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Increlex-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:		
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is the request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please specify the start	date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested	medication: *	
Severe primary insulin-like growth factor-1 deficiency (IG	F-1 deficiency; primary IGFD)	
 Growth hormone (GH) gene deletion in a patient that has developed neutralizing antibodies to growth hormone Genetic mutation of GH receptor (i.e. Laron Syndrome) Other 		
Q4. If the diagnosis is OTHER, please specify below:		
Q5. Does the patient have severe growth retardation with hei below the mean for chronological age and sex?	ght standard deviation score (SDS) more than 3 SDS	
☐ Yes	□ No	
Q6. Is the patient's IGF-1 level greater than or equal to 3 standard deviations below normal based on lab reference range for age and sex?		
☐ Yes	□ No	

EOC ID:

Increlex-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Q7. Does the patient have normal or elevated growth hormone (GH) levels based on at least one growth hormone stimulation test?		
☐ Yes	□ No	
Q8. Is there evidence of open epiphyses?		
☐ Yes	□ No	
Q9. Does the patient have allergies to mecasermin or any	component of the Increlex formulation?	
☐ Yes	□ No	
Q10. Will the medication be used for growth promotion in patients with closed epiphyses?		
☐ Yes	□ No	
Q11. Will Increlex be administered intravenously?		
☐ Yes	□ No	
Q12. Does the patient have active or suspected neoplasia?		
☐ Yes	□ No	
Q13. Please indicate the prescriber's specialty below:		
Pediatrics Endocrinol	ogist 🗌 Other	
Q14. If the prescriber's specialty is other, please describe below:		

Prescriber Signature

Date

EOC ID:

Intrarosa-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested medication:		
Dyspareunia (moderate to severe)		
Atrophic vaginitis		
Other		
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the patient's condition caused by menopause?		
☐ Yes	□ No	
Q6. Is the patient 18 years of age or older?		
	□ No	
Q7. Does the patient have any of the following (please select all that apply)?		
□ Vaginal bleeding or dysfunctional uterine bleeding of an undetermined origin		
Known or suspected estrogen-dependent neoplasia		

EOC ID:

Intrarosa-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

None of the above

Prescriber Signature

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Date

EOC ID:

Iressa-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?			
Initial therapy	Continuing therapy		
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):			
Q3. Please indicate the patient's diagnosis for the requested medication:			
Non-small cell lung cancer (metastatic)	Other		
Q4. If the patient's diagnosis is OTHER, please specify be	ow:		
Q5. Does the patient have known active epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test or Clinical Laboratory Improvement Amendments-approved facility?			
☐ Yes	□ No		
Q6. Is the medication prescribed by (or in consultation with) an oncologist?			
	□ No		
Q7. Is the patient 18 years old or older?			
☐ Yes	□ No		

EOC ID:

Iressa-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
---------------	------------------

Prescriber Signature

Date

EOC ID:

Iron Overload-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable)	:

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

EOC ID:

Iron Overload-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
☐ Yes	□ No

Prescriber Signature

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Date

EOC ID:

Itraconazole-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable)	:

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is the request for initial or continuing therapy?	
Initial therapy	Continuing therapy
Q2. For continuing therapy, please specify start date (MM/	YY):
Q3. Please indicate the diagnosis for which Itraconzole is bei	ng requested: *
 Systemic fungal infection (e.g., aspergillosis, histoplasi Onychomycosis 	mosis, blastomycosis)
Candidiasis (esophageal or oropharyngeal) that is refractory to treatment with fluconazole (ORAL SOLUTION ONLY)	
☐ Other	
Q4. If the diagnosis is OTHER, please specify below:	
Q5. For ONYCHOMYCHOSIS, has the diagnosis has been c preparation, fungal culture, or nail biopsy)?	onfirmed with a fungal diagnostic test (e.g., KOH
	□ No

EOC ID:

Itraconazole-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
---------------	------------------

EOC ID:

IVIG-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is the request for initial or continuing therapy?	
☐ Initial therapy	Continuing therapy
Q2. For continuing therapy, please specify start date (MM	I/YY):
Q3. Please indicate the diagnosis for which IVIG therapy is	being requested:
Acute and chronic immune Idiopathic Thrombocytopenie	c Purpura (ITP)
Chronic inflammatory demyelinating polyneuropathy (Cl	DP)
Primary humoral immunodeficiency syndrome (congenit syndromes [SCIDS], common variable immunodeficiency, 2	tal agammaglobulinemia, severe combined immunodeficiency X-linked immunodeficiency, Wiskott-Aldrich syndrome)
Prevention of bacterial infection in patients with hypogan cell chronic lymphocytic leukemia (CLL)	mmaglobulinemia and/or recurrent bacterial infections with B-
Prevention of coronary artery aneurysms associated wit	h Kawasaki syndrome
Motor neuropathy with multiple conduction block	
Other	
Q4. For CIDP: Has diagnosis been confirmed by a neuro	logist?
☐ Yes	□ No
Q5. If the diagnosis is OTHER, please specify below:	

EOC ID:

IVIG-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Q6. Does the patient have IgA deficiency with antibody formation and a history of hypersensitivity?		
☐ Yes	□ No	
Q7. Does the patient have a history of anaphylaxis or severe systemic reaction to human immune globulin?		
☐ Yes	□ No	
Q8. Does the patient have any risk factor(s) for acute renal failure, unless the patient will receive IVIG products at the minimum concentration available and at the minimum rate of infusion practicable?		
Yes	□ No	
Q9. If IVIG will be administered via subcutaneous route outside of a controlled healthcare setting, will appropriate treatment (eg, anaphylaxis kit) be available for managing an acute hypersensitivity reaction?		
Yes No	☐ Not applicable	

Prescriber Signature

Date

EOC ID:

Juxtapid-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested in	medication:	
Homozygous familial hypercholesterolemia	Other	
Q4. If the patient's diagnosis is OTHER, please specify below	DM:	
Q5. Has the patient had an inadequate response or intolerand	ce to statins?	
☐ Yes	□ No	
Q6. Does the patient have any of the following (please select	all that apply)?	
Moderate to severe liver impairment		
Active liver disease including unexplained persistent at	phormal liver function tests	
Pregnant		
Concomitant use with strong or moderate CYP3A4 inhi	bitors	
None of the above		

EOC ID:

Juxtapid-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Kalydeco-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start	t date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Cystic fibrosis	Other	
Q4. If the patient's diagnosis is OTHER, please specify bel	ow:	
Q5. Does the patient have 1 mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to Kalydeco potentiation based on clinical and/or in vitro assay data?		
☐ Yes	□ No	
Q6. For CONTINUING THERAPY, has the patient experienced improved or stable lung function while on Kalydeco therapy?		
☐ Yes	□ No	

EOC ID:

Kalydeco-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Kisqali-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Please indicate which medication this request is for:	🗌 Kisqali Femara	
Q2. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q3. For CONTINUING THERAPY, please provide the start	date (MM/YY):	
Q4. Please indicate the patient's diagnosis for the requested	medication:	
Breast cancer (advanced or metastatic)	Other	
Q5. If the patient's diagnosis is OTHER, please specify below:		
Q6. Please select all that apply to this patient:		
The patient is a postmenopausal female		
The patient is a premenopausal or perimenopausal female		
The patient's disease is hormone receptor (HR)-positive		
The patient's disease is human epidermal growth factor receptor 2 (HER2)-negative		
The medication will be used in combination with an aromatase inhibitor for initial endocrine-based treatment		
The medication will be used in combination with fulvestrant as initial endocrine based therapy or following		
disease progression on endocrine therapy (does not apply to Kisqali-Femara Co-pack)		

EOC ID:

Kisqali-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
□ None of the above		
Q7. Is the patient 18 years of age or older?		
Yes	No	
Q8. Is the requested medication prescribed by (or in consultation with) an oncologist?		
☐ Yes	No	
·		

Prescriber Signature

Date

EOC ID:

Korlym-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. Is this request for initial or continuing therapy?	
Initial therapy	Continuing therapy
Q2. If the request is for CONTINUING THERAPY, pleas	e provide the start date (MM/YY):
Q3. Please indicate the patient's diagnosis for the requester	ed medication: *
Hyperglycemia (in a patient with endogenous Cushing's syndrome who has failed surgery or who is ineligible for surgery)	☐ Other
Q4. If the patient's diagnosis is OTHER, please specify t	pelow:
Q5. Is the patient pregnant?	
🗌 Yes	
Patient is not female	

Expedited/Urgent

EOC ID:

Korlym-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Kuvan-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
☐ Initial therapy	Continuing Therapy	
Q2. For continuing therapy, please specify start date (MM/YY):		
Q3. Please indicate the diagnosis for which the requested me	dication is being prescribed: *	
To reduce blood phenylalanine (Phe) levels in patients with hyperphenylalaninemia (HPA)	☐ Other	
Q4. If the diagnosis is OTHER, please specify below:		
Q5. What is the patient's age?		
☐ 12 years or younger	Greater than 12 years	
Q6. What is the pretreatment blood phenylalanine (Phe) level	?	
Greater than or equal to 10mg/dl		
Between 6mg/dl and 10mg/dl		
Less than 6mg/dl		
Q7. Will blood Phe levels be checked after 1 week of therapy and periodically up to one month during a therapeutic trial?		
☐ Yes	□ No	

EOC ID:

Kuvan-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient N	ame:
-----------	------

Prescriber Name:

Q8. For CONTINUING THERAPY, is there a response to a therapeutic trial as defined by greater than or equal to 30% reduction in baseline Phe levels?

☐ Yes

□ No

Date

Prescriber Signature

EOC ID:

Kynamro-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start	date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Homozygous familial hypercholesterolemia	☐ Other	
Q4. If the patient's diagnosis is OTHER, please specify bel	DW:	
Q5. Has the patient tried and failed or had an intolerance to s	tatins?	
	□ No	
Q6. Does the patient have moderate to severe liver impairment or active liver disease including unexplained persistent abnormal liver function tests?		
	□ No	
Q7. For CONTINUING THERAPY, has the patient responded to therapy with a decrease in LDL levels?		
	□ No	

EOC ID:

Kynamro-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Lenvima-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing the	nerapy?	
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis	for the requested medication:	
Hepatocellular carcinoma (unresectabl	e)	
Renal cell carcinoma (advanced)		
Thyroid cancer, differentiated (locally re	ecurrent or metastatic, progressive)	
Other		
Q4. For RENAL CELL CARCINOMA, wi (Afinitor)?	Il the requested medication be used in combination with everolimus	
☐ Yes	□ No	
Q5. For RENAL CELL CARCINOMA, ha	is the patient received at least one (1) prior anti-angiogenic therapy?	
☐ Yes	□ No	
Q6. For THYROID CANCER, is the patie	ent's disease refractory to radioactive iodine?	
☐ Yes	□ No	
Q7. If the patient's diagnosis is OTHER, please specify below:		

EOC ID:

Lenvima-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Letairis-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:		
Primary Phone:	Specialty/facility name	(if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
☐ Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please specify the start	t date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Pulmonary arterial hypertension (PAH), WHO Group I	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. For PAH, has the diagnosis been confirmed by right heart catheterization or Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e.g., patient is frail, elderly, etc.)?		
☐ Yes	□ No	
Q6. Is the patient pregnant?		
☐ Yes	□ No	
Q7. For FEMALE PATIENTS OF CHILD-BEARING POTENT	TAL, please select all that apply:	
Pregnancy has been excluded prior to the start of therapy		
The patient has been educated about the potential hazards associated with Letairis use in pregnancy		
Women of childbearing potential will be using an IUD of		

EOC ID:

Letairis-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name: Prescriber Name:

□ None of the above

N/A - The patient is not a female of child-bearing potential

Prescriber Signature

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Date

EOC ID:

Leukine-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:		
Primary Phone:	Specialty/facility name	(if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
Initial therapy	Continuing therapy
Q2. For continuing therapy, please specify start date (MM	/YY):
Q3. Please indicate the diagnosis for which Leukine is being	requested:
Acute myelogenous leukemia (AML), following induction	chemotherapy
Bone marrow transplant (allogeneic or autologous) failur	
Myeloid reconstitution after allogeneic bone marrow trans	
Myeloid reconstitution after autologous bone marrow tran lymphoblastic leukemia (ALL), Hodgkin's lymphoma	nsplantation: Non-Hodgkin's lymphoma (NHL), acute
Peripheral stem cell transplantation: Mobilization and my transplantation	eloid reconstitution following autologous peripheral stem cell
Other	
Q4. For AML only, is there excessive (greater than or equa	al to 10%) leukemic myeloid blasts in the bone marrow or
☐ Yes	
□ No	
□ N/A - patient does not have AML	
Q5. If the diagnosis is OTHER, please specify below:	

EOC ID:

Leukine-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Q6. For patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy, please check all that apply:		
Leukine is being used for the prevention of chemotherapy-induced febrile neutropenia and the patient has experienced febrile neutropenia with a prior chemotherapy cycle		
The patient is at high risk (greater than 20%) for development is at intermediate risk (10-20%) for development is at intermediate risk (10-20%) for development is at intermediate risk (10-20%).		
The patient at low risk (less than 10%) for developing	e intent of chemotherapy is to prolong survival or cure the	
□ None of the above		
Q7. Is Leukine being requested for treatment of febrile ne Leukine (or Neupogen)?	eutropenia in a patient who has received prophylaxis with	
Yes	□ No	
Q8. Will patient receive baseline and regular monitoring of complete blood counts and platelet counts?		
☐ Yes	□ No	
Q9. Is patient at risk for infection-related complications?		
☐ Yes	□ No	
Q10. Will Leukine be administered within 24 hours preced	ding or following chemotherapy or radiotherapy?	
☐ Yes	□ No	
Q11. Is Leukine being used for prophylaxis to to increase established regimens?	the chemotherapy dose intensity or dose schedule above	
Yes	□ No	
Q12. For treatment of febrile neutropenia: Did the patient	receive Neulasta during the current chemotherapy cycle?	
☐ Yes	□ No	
Q13. Does patient have a known hypersensitivity to yeas	t-derived products?	
Yes	□ No	

EOC ID:

Leukine-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Lidocaine Patch-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable)	:

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
☐ Initial therapy	Continuing therapy
Q2. For CONTINUING THERAPY, please indicate the star	t date below (MM/YY):
Q3. Does the patient have postherpetic neuralgia?	
	□ No
Q4. Does the patient have diabetic peripheral neuropathy?	
	□ No
Q5. If the diagnosis is NOT postherpetic neuralgia or diabetic diagnosis below:	peripheral neuropathy, please specify the patient's
Q6. Has the patient previously tried and failed (or had an into medications which are labeled for the treatment of diabetic ne	,
☐ Cymbalta	
☐ Other ☐ None of the above	

EOC ID:

Lidocaine Patch-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Q7. If the medication is OTHER, please specify below:

Q8. If the patient has NOT tried any of the medications listed in the previous questions, is there a reason these medications cannot be used (i.e. contraindication, history of adverse event, etc)?

Prescriber Signature

Date

EOC ID:

Lorbrena-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start	t date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Non-small cell lung cancer (NSCLC), metastatic	☐ Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the patient anaplastic lymphoma kinase (ALK)-positive	?	
	□ No	
Q6. Has the patient experienced disease progression on any of the following (please select all that apply)?		
Alectinib (Alecensa)		
Ceritinib (Zykadia)		
Crizotinib (Xalkori) AND at least 1 other ALK inhibitor for metastatic disease		
□ None of the above		
Q7. Will the patient be taking this medication in combination with a strong CYP3A inducer?		
	□ No	

EOC ID:

Lorbrena-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Q8. Is the patient 18 years of age or older?		
☐ Yes	□ No	
Q9. Is the requested medication being prescribed by (or in consultation with) an oncologist?		
☐ Yes	□ No	

Prescriber Signature

Date

EOC ID:

Lupron-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
☐ Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please indicate Start Date (MM/YY):		
Q3. Please indicate which medication the request is for:		
Lupron Depot Injection 3.75 mg		
Lupron Depot Injection 7.5 mg		
Lupron Depot Injection 11.25		
Lupron Depot Injection 22.5 mg		
Lupron Depot Injection 30 mg		
Lupron Depot Injection 45 mg		
Other		
Q4. If medication is Other, Please specify:		
Q5. Please indicate the patient's diagnosis for the requested m	nedication:	
Prostate cancer (advanced or metastatic)		
Anemia due to uterine Leiomyomata (Fibroids)		

EOC ID:

Lupron-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Central precocious puberty (idiopathic or neurogenic) in children		
Q6. For ANEMIA DUE TO UTERINE LEIOMYOMATA	(FIBROIDS), please select all that apply:	
Patient is preoperative	None of the above	
Q7. If the patient's diagnosis is OTHER, please specify below.		
Q8. For FEMALE PATIENTS, select all that apply:		
Patient is pregnant		
Patient is breastfeeding		
Patient has undiagnosed abnormal vaginal bleeding		
☐ None of the above		
Q9. Will the patient be utilizing non-hormonal contraceptives during and for 12 weeks after therapy?		
☐ Yes	□ No	

Prescriber Signature

Date

EOC ID:

Lynparza-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate which medication this request is for:		
☐ Lynparza capsules	Lynparza tablets	
 Q4. Please indicate the patient's diagnosis for the request Breast cancer, metastatic Epithelial ovarian, fallopian tube, or primary peritoneal Ovarian cancer, advanced Other 		
Q5. For METASTATIC BREAST CANCER, please select all that apply to this patient: The patient's disease is human epidermal growth factor receptor 2 (HER2)-negative The patient has deleterious or suspected deleterious germline BRCA mutation (gBRCAm) The patient has been previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting None of the above		
Q6. For EPITHELIAL OVARIAN, FALLOPIAN TUBE, O complete or partial response to platinum-based chemot	R PRIMARY PERITONEAL CANCER, has the patient had a herapy?	

EOC ID:

Lynparza-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Yes	□ No		
Q7. For ADVANCED OVARIAN CANCER, please select all that apply to this patient:			
 The patient has deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer The patient has been treated with three (3) or more prior lines of chemotherapy None of the above 			
Q8. If the patient's diagnosis is OTHER, please specify below:			

Prescriber Signature

Date

EOC ID:

Mekinist-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is the request for initial or continuing therapy?			
☐ Initial therapy	Continuing therapy		
Q2. For CONTINUING THERAPY, please provide the start	date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested r	nedication:		
Melanoma (adjuvant treatment)			
	Melanoma (unresectable or metastatic)		
Non-small cell lung cancer (metastatic) (with BRAF V600E mutation) Thyroid cancer, anaplastic (locally advanced or metastatic) (with BRAF V600E mutation)			
Q4. If the patient's diagnosis is OTHER, please specify below:			
Q5. Does the patient have documented BRAF V600E or V600	K mutations as detected by an FDA-approved test?		
	□ No		
Q6. Is the requested medication being prescribed by an oncologist?			
☐ Yes	□ No		

EOC ID:

Mekinist-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Mektovi-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start da	ate (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Melanoma (unresectable or metastatic malignant)	☐ Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Does the patient have BRAF V600E or V600K mutation a	is detected by an FDA-approved test?	
	□ No	
Q6. Will Mektovi be used in combination with Braftovi (encorafenib)?		
	□ No	
Q7. Is the requested medication being prescribed by (or in consultation with) an oncologist?		
	□ No	
Q8. Is the patient 18 years of age or older?		

EOC ID:

Mektovi-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
☐ Yes	□ No

Prescriber Signature

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Date

EOC ID:

Miglustat-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested r	nedication:	
Gaucher disease, type 1 (mild to moderate)	☐ Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the patient a candidate for enzyme replacement therap	y?	
	□ No	
Q6. Is the patient 18 years of age or older?		
☐ Yes	□ No	

EOC ID:

Miglustat-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Multiple Sclerosis-5 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
☐ Initial therapy	Continuing therapy
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):	
Q3. For CONTINUING THERAPY, has the patient exper slowed progression of disease)?	ienced an objective response to therapy (such as no or
☐ Yes	□ No
Q4. Please indicate which medication this request is for: Aubagio Avonex Betaseron Gilenya Glatiramer Plegridy Tecfidera	
Q5. For AUBAGIO, please select all that apply to this patient: Patient has severe hepatic impairment Patient is currently being treated with leflunomide Patient is pregnant	

EOC ID:

Multiple Sclerosis-5 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
 Patient is a woman of child-bearing potential who is NOT using reliable contraception None of the above 	
Q6. For GILENYA, please select all that apply to this p	atient:
Recent (within the last 6 months) occurrence of: myocardial infarction, unstable angina, stroke, transient ischemic attack, decompensated heart failure requiring hospitalization, or Class III/IV heart failure	
History or presence of Mobitz Type II 2nd degree or 3rd degree AV block or sick sinus syndrome, unless patient has a pacemaker	
Baseline QTc interval greater than or equal to 500 ms	
Receiving concurrent treatment with Class Ia or Class III anti-arrhythmic drugs (such as quinidine, procainamide, amiodarone, or sotalol)	
\square None of the above	
Q7. For GILENYA, will the patient be observed for signs and symptoms of bradycardia in a controlled setting for at least 6 hours after the first dose?	
☐ Yes	□ No
Q8. For GLATIRAMER, is the patient 18 years of age or older?	
☐ Yes	□ No
Q9. Please indicate the patient's diagnosis for the requested medication:	
Multiple sclerosis (relapsing forms)	
 First clinical episode and patient has MRI features consistent with multiple sclerosis Other 	
Q10. If the patient's diagnosis is OTHER, please specify below:	

Prescriber Signature

Date

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

EOC ID:

Natpara-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
Initial therapy	Continuing therapy
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested medication:	
Hypocalcemia due to hypoparathyroidism	Other
Q4. If diagnosis is OTHER, please specify:	
Q5. Is the Prescriber certified in the NATPARA REMS program?	
☐ Yes	No

EOC ID:

Natpara-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
Prescriber Signature	Date

EOC ID:

Nerlynx-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Breast cancer (early stage HER2-overexpressed)	Other	
Q4. If the patient's diagnosis is OTHER, please specify be	low:	
Q5. Will Nerlynx be used in a patient who has been previous	ly treated with trastuzumab-based therapy?	
	□ No	
Q6. Is the patient 18 years of age or older?		
	□ No	
Q7. Is Nerlynx prescribed by (or in consultation with) an oncologist?		
☐ Yes	□ No	

EOC ID:

Nerlynx-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Ninlaro-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
☐ Initial therapy	Continuing therapy	
Q2. For continuing therapy, please specify start date (MM/	(Y).	
Q3. Please indicate the patient's diagnosis for the requested r	nedication:	
Multiple myeloma	Other	
Q4. If the patient's diagnosis is OTHER, please specify below.		
Q5. Will the requested medication be used in combination wit	h lenalidomide (Revlimid) and dexamethasone?	
☐ Yes	□ No	
Q6. Has the patient received at least one (1) prior therapy?		
☐ Yes	□ No	
Q7. Is the patient 18 years old or older?		
☐ Yes	□ No	
Q8. Is the medication prescribed by or in consultation with a hematologist/oncologist?		

EOC ID:

Ninlaro-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
☐ Yes	□ No

Prescriber Signature

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Date

EOC ID:

Northera-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
☐ Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please	provide the start date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Neurogenic orthostatic hypotension (NOH)	Other	
Q4. If the patient's diagnosis is OTHER, please specify be	elow:	
Q5. If the patient has a diagnosis of NOH, is the NOH due to any of the following (please select all that apply)? Primary autonomic failure (Parkinson's disease, multiple system atrophy, or pure autonomic failure) Dopamine beta-hydroxylase deficiency Non-diabetic autonomic neuropathy None of the above		
Q6. If the patient has NOH that is NOT caused by any of t cause of the patient's NOH:	he issues listed in the previous question, please specify the	
Q7. Does the patient have any of the following symptoms (pl	lease select all that apply)?	

EOC ID:

Northera-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
 Lightheadedness "Feeling that you are about to black out" None of the above 	

Prescriber Signature

Date

EOC ID:

Nucala-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please p	provide the start date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested	medication: *	
Severe asthma (Add-on maintenance treatment)		
Eosinophilic granulomatosis with polyangiitis (EGPA)		
Other		
Q4. For ASTHMA, does the patient have an eosinophilic phenotype?		
	□ No	
Q5. If the patient's diagnosis is OTHER, please specify below:		
Q6. Is the patient 12 years of age or older?		
	□ No	
Q7. Is the requested medication being prescribed by a pulmonologist or immunologist?		
🗌 Yes	□ No	

EOC ID:

Nucala-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
---------------	------------------

Prescriber Signature

Date

EOC ID:

Nuedexta-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therap	by?	
☐ Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please sp	ecify the start date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the	ne requested medication:	
Pseudobulbar affect (PBA)	Other	
Q4. If the patient's diagnosis is OTHER, plea	se specify below:	

EOC ID:

Nuedexta-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
---------------	------------------

hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

EOC ID:

Nuplazid-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
☐ Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested	d medication:	
Parkinson's disease - Psychotic disorder	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the patient experiencing hallucinations and/or delusions?		
☐ Yes	□ No	

EOC ID:

Nuplazid-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
Prescriber Signature	Date

EOC ID:

Octreotide-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For continuing therapy, please specify start date (MM/YY):		
Q3. Please indicate the diagnosis for which Octreotide is be	ing requested:	
Metastatic carcinoid tumors		
Watery diarrhea associated with vasoactive intestinal pe	eptide-secreting tumors (VIPomas)	
Other		
Q4. If the patient's diagnosis is OTHER, please specify below:		
1		

EOC ID:

Octreotide-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
Prescriber Signature	Date

EOC ID:

Opsumit-6 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please specify the start	date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested n	nedication:	
Pulmonary arterial hypertension (PAH) (World Health Organization group 1)	☐ Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Has diagnosis been confirmed by right heart catheterizati	on?	
☐ Yes	□ No	
Q6. For FEMALE PATIENTS, please select all that apply:		
 The patient is enrolled in the OPSUMIT REMS program The patient is NOT pregnant The patient will use an IUD or two appropriate contraceptive methods 		
□ N/A - The patient is not female or not of child-bearing p	otential	

EOC ID:

Opsumit-6 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Orkambi-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. For CONTINUING THERAPY, is the patient tolerating following (please select all that apply)?	and responding to the medication as evidenced by the	
Improved FEV1		
🗌 Weight gain		
Decreased exacerbations		
Other		
□ None of the above		
Q4. Please indicate the patient's diagnosis for the requested medication:		
Cystic Fibrosis (CF)	Other	
Q5. If diagnosis is OTHER, please specify below:		
Q6. Is the patient homozygous for the F508del mutation in the CFTR gene as confirmed by an FDA-approved CF test?		
☐ Yes	□ No	
	No	

EOC ID:

Orkambi-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:

Q7. Is the medication prescribed by, or in conjunction with, a pulmonologist or is from a CF center accredited by the **Cystic Fibrosis Foundation?**

🗌 Yes

🗌 No

Prescriber Signature

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Date

EOC ID:

Orilissa-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please indicate the star	t date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Endometriosis (with moderate to severe pain)	☐ Other	
Q4. If the patient's diagnosis is OTHER, please specify be	ow:	
Q5. Is the patient 18 years of age or older?		
	□ No	
Q6. Does the patient have any of the following (please select all that apply)?		
Pregnancy		
C Known osteoporosis		
Severe hepatic impairment		
Current use of strong organic anion transporting polypeptide (OATP) 1B1 inhibitors		
□ None of the above		

EOC ID:

Orilissa-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Osphena-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
☐ Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested r	nedication:	
Dyspareunia (moderate to severe)		
Atrophic vaginitis		
Moderate to severe vaginal dryness due to menopause		
Other		
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the patient's condition caused by menopause?		
☐ Yes	□ No	
Q6. Is the patient 18 years of age or older?		
☐ Yes	□ No	
Q7. Does the patient have any of the following (please select all that apply)?		
Acute thromboembolism or a past history of thromboembolic disease (including patients with a history of DVT,		

EOC ID:

Osphena-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
pulmonary embolism, retinal vein thrombosis, stroke, or myocardial infarction)	
 Known or suspected estrogen-dependent neoplasia Known or suspected pregnancy 	
☐ Vaginal bleeding or dysfunctional uterine bleeding of an undetermined origin	
□ None of the above	

Prescriber Signature

Date

EOC ID:

Oxandrolone-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?			
Initial therapy	Continuing therapy		
Q2. For continuing therapy, please specify start date (MM/	YY):		
Q3. Please indicate the patient's diagnosis for the requested	medication: *		
To promote weight gain (adjunct therapy)	☐ Other		
Q4. If the diagnosis is OTHER, please specify below:			
Q5. Does the patient have any of the following exclusions? (Please select all that apply):			
Known or suspected carcinoma of the prostate or breast (in male patients)			
Carcinoma of the breast in a female patient with hypercalcemia			
Nephrosis (the nephrotic phase of nephritis)			
Hypercalcemia			
Pregnancy			
□ None of the above			

EOC ID:

Oxandrolone-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Oxervate-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Please attach any pertinent medical history or information for this patient that may support approval. Please answer the following questions and sign.

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the re-	equested medication:	
Neurotrophic keratitis	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the medication being prescribed by or in consultation with an ophthalmologist or optometrist?		
☐ Yes	□ No	

Prescriber Signature

Date

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

EOC ID:

PCSK9 Inhibitors-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy? Initial therapy Q2. For CONTINUING THERAPY, please specify the start date (MM/YY): Q3. Please indicate which medication this request is for: Praluent Q4. Please indicate the patient's diagnosis for the requested medication: Heterozygous familial hypercholesterolemia (HeFH) Heterozygous familial hypercholesterolemia (HeFH) Clinical atherosclerotic cardiovascular disease (CVD) Established CVD (to reduce the risk of MI, stroke, coronary revascularization) Other Q5. For HeFH, has the diagnosis been confirmed by either of the following? Genotyping Simon Broome criteria None of the above Q6. For HeFH, if the diagnosis was confirmed by Simon Broome criteria, please select all that apply to this patient:		
Q2. For CONTINUING THERAPY, please specify the start date (MM/YY): Q3. Please indicate which medication this request is for: Praluent Repatha Q4. Please indicate the patient's diagnosis for the requested medication: Heterozygous familial hypercholesterolemia (HeFH) Homozygous familial hypercholesterolemia (HeFH) Clinical atherosclerotic cardiovascular disease (CVD) Established CVD (to reduce the risk of MI, stroke, coronary revascularization) Other Q5. For HeFH, has the diagnosis been confirmed by either of the following? Genotyping Simon Broome criteria None of the above Q6. For HeFH, if the diagnosis was confirmed by Simon Broome criteria, please select all that apply to this patient:	Q1. Is this request for initial or continuing therapy?	
Q3. Please indicate which medication this request is for: Praluent Repatha Q4. Please indicate the patient's diagnosis for the requested medication: Heterozygous familial hypercholesterolemia (HeFH) Homozygous familial hypercholesterolemia (HeFH) Clinical atherosclerotic cardiovascular disease (CVD) Established CVD (to reduce the risk of MI, stroke, coronary revascularization) Other Q5. For HeFH, has the diagnosis been confirmed by either of the following? Genotyping Simon Broome criteria None of the above	Initial therapy	Continuing therapy
Praluent Repatha Q4. Please indicate the patient's diagnosis for the requested medication: Heterozygous familial hypercholesterolemia (HeFH) Homozygous familial hypercholesterolemia (HoFH) Clinical atherosclerotic cardiovascular disease (CVD) Established CVD (to reduce the risk of MI, stroke, coronary revascularization) Other Q5. For HeFH, has the diagnosis been confirmed by either of the following? Genotyping Simon Broome criteria None of the above	Q2. For CONTINUING THERAPY, please specify the start	date (MM/YY):
Praluent Repatha Q4. Please indicate the patient's diagnosis for the requested medication: Heterozygous familial hypercholesterolemia (HeFH) Homozygous familial hypercholesterolemia (HoFH) Clinical atherosclerotic cardiovascular disease (CVD) Established CVD (to reduce the risk of MI, stroke, coronary revascularization) Other Q5. For HeFH, has the diagnosis been confirmed by either of the following? Genotyping Simon Broome criteria None of the above Q6. For HeFH, if the diagnosis was confirmed by Simon Broome criteria, please select all that apply to this patient:		
Q4. Please indicate the patient's diagnosis for the requested medication: Heterozygous familial hypercholesterolemia (HeFH) Homozygous familial hypercholesterolemia (HoFH) Clinical atherosclerotic cardiovascular disease (CVD) Established CVD (to reduce the risk of MI, stroke, coronary revascularization) Other Q5. For HeFH, has the diagnosis been confirmed by either of the following? Genotyping Simon Broome criteria None of the above Q6. For HeFH, if the diagnosis was confirmed by Simon Broome criteria, please select all that apply to this patient:	Q3. Please indicate which medication this request is for:	
 ☐ Heterozygous familial hypercholesterolemia (HeFH) ☐ Homozygous familial hypercholesterolemia (HoFH) ☐ Clinical atherosclerotic cardiovascular disease (CVD) ☐ Established CVD (to reduce the risk of MI, stroke, coronary revascularization) ☐ Other Q5. For HeFH, has the diagnosis been confirmed by either of the following? ☐ Genotyping ☐ Simon Broome criteria ☐ None of the above Q6. For HeFH, if the diagnosis was confirmed by Simon Broome criteria, please select all that apply to this patient: 	Praluent	Repatha
 Homozygous familial hypercholesterolemia (HoFH) Clinical atherosclerotic cardiovascular disease (CVD) Established CVD (to reduce the risk of MI, stroke, coronary revascularization) Other Q5. For HeFH, has the diagnosis been confirmed by either of the following? Genotyping Simon Broome criteria None of the above Q6. For HeFH, if the diagnosis was confirmed by Simon Broome criteria, please select all that apply to this patient: 	Q4. Please indicate the patient's diagnosis for the requested in	medication:
 Clinical atherosclerotic cardiovascular disease (CVD) Established CVD (to reduce the risk of MI, stroke, coronary revascularization) Other Q5. For HeFH, has the diagnosis been confirmed by either of the following? Genotyping Simon Broome criteria None of the above Q6. For HeFH, if the diagnosis was confirmed by Simon Broome criteria, please select all that apply to this patient: 		
 Established CVD (to reduce the risk of MI, stroke, coronary revascularization) Other Q5. For HeFH, has the diagnosis been confirmed by either of the following? Genotyping Simon Broome criteria None of the above Q6. For HeFH, if the diagnosis was confirmed by Simon Broome criteria, please select all that apply to this patient: 		
 □ Other Q5. For HeFH, has the diagnosis been confirmed by either of the following? □ Genotyping □ Simon Broome criteria □ None of the above Q6. For HeFH, if the diagnosis was confirmed by Simon Broome criteria, please select all that apply to this patient: 		
Q5. For HeFH, has the diagnosis been confirmed by either of the following? Genotyping Simon Broome criteria None of the above Q6. For HeFH, if the diagnosis was confirmed by Simon Broome criteria, please select all that apply to this patient:		ry revascularization)
 ☐ Genotyping ☐ Simon Broome criteria ☐ None of the above Q6. For HeFH, if the diagnosis was confirmed by Simon Broome criteria, please select all that apply to this patient: 		
 Simon Broome criteria None of the above Q6. For HeFH, if the diagnosis was confirmed by Simon Broome criteria, please select all that apply to this patient: 	Q5. For HeFH, has the diagnosis been confirmed by either	of the following?
Q6. For HeFH, if the diagnosis was confirmed by Simon Broome criteria, please select all that apply to this patient:	Genotyping	
Q6. For HeFH, if the diagnosis was confirmed by Simon Broome criteria, please select all that apply to this patient:	Simon Broome criteria	
	□ None of the above	
☐ Total cholesterol greater than 290 mg/dL	Q6. For HeFH, if the diagnosis was confirmed by Simon Br	oome criteria, please select all that apply to this patient:
	Total cholesterol greater than 290 mg/dL	

EOC ID:

PCSK9 Inhibitors-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
LDL cholesterol greater than 190 mg/dL Tendon xanthomas in the patient, 1st degree relative (parent, sibling, child), or 2nd degree relative (grandparent, uncle, aunt) DNA-based evidence of LDL receptor mutation, familial defective apo B-100, or PCSK9 mutation None of the above		
 Q7. For HoFH, has the diagnosis been confirmed by an Genotyping History of untreated LDL-C greater than 500 mg Xanthoma before 10 years of age Documentation of HeFH in both parents None of the above 		
Q8. For CVD, has the patient experienced any of the fo Acute coronary syndrome History of myocardial infarction Stable or unstable angina Coronary or other arterial revascularization Stroke Transient ischemic attack (TIA) Peripheral arterial disease (PAD) presumed to b None of the above		
Q9. If the patient's diagnosis is OTHER, please specify	/ below:	
Q10. Please provide the patient's baseline and current LD	DL-C cholesterol levels below:	
Q11. Please indicate the patient's age: Less than 13 years of age 13-17 years of age 18 years of age or older		
 Statins are contraindicated or not tolerated by the p None of the above 	ion with maximally tolerated high-intensity statin therapy patient	
Q13. If statins are contraindicated or not tolerated by the patient, please explain below:		

EOC ID:

PCSK9 Inhibitors-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Q14. Is the medication being prescribed by (or in consulta	ation with) any of the following?	
Cardiologist		
Endocrinologist		
Lipid specialist		
None of the above		
Q15. For CONTINUING THERAPY, please select all that apply to this patient:		
The patient is tolerating the medication		
The requested medication will continue to be used in combination with maximally tolerated statin		
Statin therapy is contraindicated or not tolerated by the patient		
□ None of the above		

Prescriber Signature

Date

EOC ID:

Pegasys-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or conti	nuing therapy?		
Initial therapy	🗌 Continui	ng therapy	
Q2. For continuing therapy, please specify start date (MM/YY):			
Q3. Please indicate the patient's dia	ignosis for the requested medication: *		
Chronic Hepatitis B	Chronic Hepatitis C	Other	
Q4. For CHRONIC HEPATITIS C, please indicate the patient's genotype below:			
Q5. For CHRONIC HEPATITIS C	, is the patient treatment naive or exper	ienced?	
Treatment naive (i.e. no pr Hepatitis C)		ent experienced (i.e. has received treatment C in the past)	
Q6. For CHRONIC HEPATITIS C, if the patient is treatment-experienced, please list all previous treatment regimens as well as the response to the regimen (i.e. non-responder, relapser, etc):			
Q7. For CHRONIC HEPATITIS C, will Pegasys be used in conjunction with Sovaldi?			
Yes	🗌 No		
Q8. If the patient's diagnosis is OTHER, please specify below:			

EOC ID:

Pegasys-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Q9. Does the patient have any of the following? (please s	elect all that apply):	
Decompensated liver disease		
Autoimmune hepatitis Concomitant administration of didanosine with riba	virin in patients on infected with HIV	
☐ None of the above		
Q10. Please select the prescriber's specialty:		
☐ Infectious disease (ID)		
☐ Oncology ☐ Other		
	h a haun	
Q11. If the prescriber specialty is Other, please describe below:		
Q12. Will the patient be monitored for evidence of depression?		
☐ Yes	□ No	
Q13. Please indicate the patient's age below:		
0 to 2 years		
3 - 4 years old		
 5-17 years 18 years old or older 		

Prescriber Signature

Date

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

EOC ID:

Pomalyst-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is the request for initial or continuing therapy?		
Initial therapy Continuing therapy		
Q2. For continuing therapy, please specify start date (MM/YY):		
Q3. Please indicate the patient's diagnosis below:		
☐ Multiple myeloma, in combination with dexamethasone ☐ Other		
Q4. If the patient's diagnosis is OTHER, please specify below.		
Q5. Please select all that apply to this patient:		
Patient has received at least two (2) prior therapies including lenalidomide (Revlimid) and a proteasome inhibitor (bortezomib (Velcade))		
Disease has progressed within 60 days of completion of the last therapy		
Patient has been counseled about the use of reliable contraception before, during and 1 month after initiation of therapy		
Patient has been assessed to determine if prophylactic aspirin or antithrombotic treatment (warfarin, clopidogrel) will need to be taken to reduce the risk of VTE (embolism, stroke)		
Patient is registered and certified to be compliant with Pomalyst REMS (Risk Evaluation and Mitigation Strategy) program		
□ None of the above		

EOC ID:

Pomalyst-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Q6. For FEMALES OF CHILD-BEARING POTENTIAL, please select all that apply:			
 Two (2) negative pregnancy tests have been obtained prior to initiation of therapy Patient will receive pregnancy test monthly during therapy Patient is male or not of reproductive potential None of the above 			
Q7. Please indicate the prescriber's specialty below:			
Oncologist Hematolog	ist 🗌 Other		
Q8. If the answer is OTHER, please specify:			

Prescriber Signature

Date

EOC ID:

Promacta-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is request for initial or continuing therapy?		
☐ Initial therapy	Continuing therapy	
Q2. For continuing therapy, please specify start date (MM/	YY):	
Q3. Please indicate the diagnosis for which the requested me	edication is being prescribed:	
Idiopathic thrombocytopenic purpura (ITP)		
Hepatitis C infection associated thrombocytopenia		
Severe aplastic anemia with insufficient response to immunosuppressive therapy or in combination with		
immunosuppressive therapy		
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Has the patient had an insufficient response or intolerand	ce to corticosteroids, immunoglobulins, or splenectomy?	
☐ Yes	□ No	
Q6. Is the platelet (Plt) count at time of diagnosis: less than 30,000/mcL OR less than or equal to 50,000/mcL with significant mucous membrane bleeding or risk factors for bleeding?		
☐ Yes	□ No	

EOC ID:

Promacta-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Q7. Will liver function be assessed pretreatment and regularly throughout therapy?		
☐ Yes	□ No	
Q8. Are alanine aminotransferase levels greater than or equal to 3 times the upper limit of normal with any of the following characteristics: progressive, persistent, accompanied by increased bilirubin or symptoms of liver injury or evidence of hepatic decompensation?		
☐ Yes	□ No	
Q9. For CONTINUING therapy: Has the platelet count responded to Promacta? (Response defined as: Platelet count has increased to at least 50,000/mcL)		
☐ Yes	□ No	
Q10. For CONTINUING therapy and patient's platelet count less than 50,000/microliter: Has platelet count increased to a level sufficient to avoid clinically important bleeding after at least 4 weeks of Promacta at the maximum dose?		
Yes	□ No	
Q11. For CONTINUING therapy: If platelet counts rise above 200,000/mcL with Promacta, will therapy be adjusted to maintain the minimal count needed to reduce the patient's risk for bleeding?		
☐ Yes	□ No	

Prescriber Signature

Date

EOC ID:

Regranex-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
Initial therapy	Continuing therapy
Q2. For CONTINUING THERAPY, please indicate the start date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested medication below:	
Diabetic neuropathic ulcer	Other
Q4. If the patient's diagnosis is OTHER, please specify below:	
Q5. Will treatment be given in combination with ulcer wound care (such as debridement, infection control, and/or pressure relief)?	
☐ Yes	□ No

EOC ID:

Regranex-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Date

Prescriber Signature

EOC ID:

Revlimid-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
Initial Therapy	Continuing Therapy
Q2. For CONTINUING THERAPY please indicate the start of	late (MM/YY):
Q3. Please indicate the patient's diagnosis: *	
Mantle cell lymphoma	
Multiple Myeloma	
Transfusion-dependent anemia	
Other	
Q4. For MANTLE CELL LYMPHOMA, has the patient relaps which included bortezomib)?	ed or progressed after two (2) prior therapies (one of
☐ Yes	□ No
Q5. For MULTIPLE MYELOMA, please select all that apply:	
Revlimid will be used in combination with dexamethasone	□ None of the above
Q6. For TRANSFUSION-DEPENDENT ANEMIA, is the condition due to low- or intermediate-1-risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities?	

EOC ID:

Revlimid-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
🗌 Yes	□ No	
Q7. If the patient's diagnosis is OTHER, please specify	below:	
Q8. Is the patient enrolled in the Revlimid REMS Program	ı?	
☐ Yes	□ No	
Q9. Is the patient pregnant?		
☐ Yes	□ No	
Q10. Have male and female patients of child-bearing potential been instructed on the importance of proper utilization of appropriate contraceptive methods for Revlimid use?		
☐ Yes	□ No	
Q11. Will the patient be monitored for signs and symptoms of thromboembolism?		
☐ Yes	□ No	

Prescriber Signature

Date

EOC ID:

Rubraca-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the star	t date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Epithelial ovarian, fallopian tube, or primary peritoneal cancer (deleterious germline and/or somatic BRCA mutation associated)		
 Epithelial ovarian, fallopian tube, or primary peritoneal Other 	cancer (recurrent)	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the patient 18 years of age or older?		
	□ No	
Q6. Is Rubraca being prescribed by a hematologist or oncologist?		
□ Yes	□ No	
Q7. Please select all that apply to this patient:		
The patient is BRCA mutation positive as detected by an approved FDA laboratory test		

EOC ID:

Rubraca-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
 The patient has had previous trial and failure with two or more chemotherapy regimens The patient has had a complete or partial response to platinum-based chemotherapy Rubraca will be used as monotherapy The provider agrees to perform a complete blood count (CBC) at baseline and monthly thereafter None of the above 		
Q8. For WOMEN OF REPRODUCTIVE POTENTIAL, will an effective method of contraception be used during therapy and for 6 months after the last dose?		
 No N/A - The patient is not a female of reproductive potential 		

Prescriber Signature

Date

EOC ID:

Rydapt-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
☐ Initial therapy	Continuing therapy
Q2. If the request is for CONTINUING THERAPY, please p	rovide the start date (MM/YY):
Q3. Please indicate the patient's diagnosis for the requested r	nedication:
Acute myeloid leukemia (AML), newly diagnosed	
Mast cell leukemia (MCL)	
Systemic mastocytosis	
Other	
Q4. For ACUTE MYELOID LEUKEMIA, please select which	n of the following (if any) apply to this patient:
The patient is treatment naïve	
The patient is FLT3 mutation-positive	
Rydapt will be used in combination with standard cy	tarabine and daunorubicin induction and cytarabine
consolidation chemotherapy	
Q5. If the patient's diagnosis is OTHER, please specify belo	DW:
Q6. Is the patient 18 years of age or older?	
L	

EOC ID:

Rydapt-1 Medicare

Phone: 800-361-4542

Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
☐ Yes	□ No	
Q7. Is the requested medication being prescribed by (or in consultation with) an oncologist?		
☐ Yes	□ No	
Q8. Does the patient have angioedema?		
☐ Yes	□ No	

Prescriber Signature

Date

EOC ID:

Samsca-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is the request for initial or continuing therapy?	
Initial therapy	Continuing therapy
Q2. For continuing therapy, please specify start date (MM/	YY):
Q3. Please indicate the patient's diagnosis for the requested	medication:
Hypervolemic hyponatremia	
Euvolemic hyponatremia	
Other	
Q4. If the patient's diagnosis is OTHER, please specify bel	ow:
Q5. Does the patient have anuria?	
☐ Yes	□ No
Q6. Does the patient require an URGENT increase in serum s	sodium?
	□ No
Q7. Is the patient able to sense and respond to thirst?	
☐ Yes	□ No

EOC ID:

Samsca-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Q8. Will Samsca be used in combination with a strong CYP3A inhibitor (such as clarithromycin or ketoconazole)?		
Yes	□ No	
Q9. Will Samsca be initiated or re-initiated in a hospital where serum sodium can be monitored closely?		
☐ Yes	□ No	

Prescriber Signature

Date

EOC ID:

Sildenafil-5 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?			
Initial therapy	Continuing therapy		
Q2. For continuing therapy, please specify start date (MM/	YY):		
Q3. Please indicate the patient's diagnosis for the requested	medication:		
Pulmonary arterial hypertension (PAH) (WHO Group I)	Other		
Q4. If the patient's diagnosis is OTHER, please specify below:			
Q5. Has PAH been confirmed by right heart catheterization or by Doppler echocardiogram if patient is unable to undergo a right heart catheterization (e.g., patient is frail, elderly, etc.)?			
☐ Yes	□ No		
Q6. Is the patient currently on nitrate therapy?			
☐ Yes	□ No		

EOC ID:

Sildenafil-5 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Somatuline-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested Acromegaly Unresectable, well- or moderately-differentiated, locally a neuroendocrine tumor Hyperthyroidism secondary to thyrotropinoma		
Carcinoid syndrome		
Q4. If diagnosis is ACROMEGALY, please check all that a	ipply:	
Patient has had an inadequate response to surgery		
Surgery and/or radiotherapy is not an option for this None of the above	s patient	
Q5. If diagnosis is OTHER, please specify.		
Q6. Is the patient 18 years of age or older?		

EOC ID:

Somatuline-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
☐ Yes	□ No

Prescriber Signature

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Date

EOC ID:

Somavert-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Acromegaly, Second-line therapy	Other	
Q4. If the patient's diagnosis is OTHER, please specify bel	low:	
Q5. Has the diagnosis of acromegaly been confirmed by an elevated IGF-1 level or elevated GH level with a glucose tolerance test?		
☐ Yes	□ No	
Q6. Has the patient tried and failed a 3 month trial of Sandostatin or Somatuline?		
☐ Yes	□ No	
Q7. Is the medication being prescribed by an endocrinologist?		
	□ No	
Q8. Will Somavert be administered IV?		

EOC ID:

Somavert-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
☐ Yes	□ No	
Q9. Will the patient also be using Sandostatin or Somatuline while on Somavert therapy?		
☐ Yes	□ No	
Q10. FOR CONTINUING THERAPY, has the patient experienced a reduction in IGF-1 level from baseline?		
☐ Yes	□ No	

Prescriber Signature

Date

EOC ID:

Sprycel-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?			
Initial therapy	Continuing therapy		
Q2. For continuing therapy, please specify start date (MM/	YY).		
Q3. Please indicate the patient's diagnosis for the requested	medication: *		
 Chronic myeloid leukemia (CML) in chronic phase, Philadelphia chromosome-positive (Ph+) [newly diagnosed] Chronic myeloid leukemia (CML) in chronic, accelerated, myeloid or lymphoid blast phase, Philadelphia chromosome-positive (Ph+) Acute lymphoblastic leukemia (ALL), Philadelphia chromosome-positive (Ph+) Newly diagnosed Ph+ Acute lymphoblastic leukemia (ALL) in combination with chemotherapy Other 			
Q4. If the patient's diagnosis is OTHER, please specify below:			
Q5. Has the patient had resistance or intolerance to prior the	rapy?		
	□ No		
Q6. If yes, did the prior therapy include imatinib (Gleevec)?			
☐ Yes	No		

EOC ID:

Sprycel-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Q7. Is the medication being prescribed by an oncologist?		
Yes	□ No	
Prescriber Signature	Date	

EOC ID:

Stivarga-5 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
☐ Initial therapy	Continuing therapy	
Q2. For continuing therapy, please specify start date (MM/	YY).	
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Colorectal cancer (metastatic)		
Gastrointestinal stromal tumors (GIST) (locally advanced, unresectable or metastatic)		
Hepatocellular carcinoma (previously treated with sorafenib [Nexavar])		
Other		
Q4. For COLORECTAL CANCER, is the patient's disease KRAS mutation negative?		
☐ Yes	□ No	
Q5. For COLORECTAL CANCER, please indicate which o select all that apply):	f the following the patient has previously tried (please	
Fluoropyrimidine-, oxaliplatin, and irinotecan-based chemotherapy		
Bevacizumab (Avastin)		
Panitumumab (Vectibix)		
Cetuximab (Erbitux)		

EOC ID:

Stivarga-5 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Q6. If medication is Other, please specify:		
Q7. For GASTROINTESTINAL STROMAL TUMORS, please select which of the following the patient has previously tried (please select all that apply):		
Imatinib mesylate (Gleevec)		
Sunitinib malate (Sutent)		
Other		
Q8. If OTHER, please specify:		
Q9. If the patient's diagnosis is OTHER, please specify below:		
Q10. Is the patient 18 years of age or older?		
☐ Yes	□ No	
Q11. Is the requested medication being prescribed by an oncologist?		
☐ Yes	□ No	

Prescriber Signature

Date

EOC ID:

Sutent-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therap	ру?		
Initial therapy	Continuing therapy		
Q2. If the request is for CONTINUING THER	APY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis belo)W: *		
Progressive, well-differentiated pancreatic neuroendocrine tumors in a patient with unresectable locally advanced or metastatic disease			
Renal cell carcinoma, advanced/metastatic			
Gastrointestinal stromal tumor			
Adjuvant treatment in renal cell carcinoma for patients at high risk of recurrence following nephrectomy			
Other			
Q4. If the diagnosis is OTHER, please specif	Q4. If the diagnosis is OTHER, please specify.		
Q5. For GASTROINTESTINAL STROMAL TUN Gleevec (imatinib)?	IORS, has the patient had disease progression on or intolerance to		
☐ Yes	□ No		
Q6. Is the patient 18 years of age or older?			
☐ Yes	□ No		

EOC ID:

Sutent-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Prescriber Name:
□ No

Prescriber Signature

Date

EOC ID:

Sylatron-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
Initial therapy	Continuing therapy
Q2. If the request is for CONTINUING THERAPY, please p	rovide the start date (MM/YY):
Q3. Please indicate the patient's diagnosis below:	
Malignant Melanoma with microscopic or gross nodal involvement	Other
Q4. If the diagnosis is OTHER, please specify:	
Q5. Does the patient have any of the following (please select a	all that apply)?
Autoimmune hepatitis	
Hepatic decompensation (Child-Pugh score greater than 6 [Class B or C])	
None of the above	
Q6. For melanoma with microscopic or gross nodal involvement, is Sylatron being used as adjuvant treatment within 84 days of definitive surgical resection, including complete lymphadenectomy?	
☐ Yes	No

EOC ID:

Sylatron-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Symdeko-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Cystic fibrosis	Other	
Q4. If the patient's diagnosis is OTHER, please specify be	low:	
Q5. Please select if any of the following apply to this patient:		
The patient is homozygous for the F508del mutation		
The patient has a mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is responsive to tezacaftor/ivacaftor verified by a FDA-approved CF mutation test None of the above		
Q6. Is the patient 12 years of age or older?		
	□ No	

EOC ID:

Symdeko-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Symlin-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For INITIAL THERAPY, does the patient have inade 9%)?	equate glycemic control (HbA1c greater than 7% but less than	
☐ Yes	□ No	
Q3. For CONTINUING THERAPY, please indicate the start date (MM/YY):		
Q4. For CONTINUING THERAPY, has the patient taken Symlin in the previous 6 months and demonstrated a reduction in HbA1c since initiating Symlin therapy?		
☐ Yes	□ No	
Q5. Please indicate the patient's diagnosis for the requested medication:		
Diabetes mellitus (type 1 or type 2), adjunctive treatment	Other	
Q6. If the patient's diagnosis is OTHER, please specify	below:	
Q7. Is the patient currently receiving optimal mealtime insulin therapy?		
☐ Yes	□ No	

EOC ID:

Symlin-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Prescriber Name:		
Q8. Does the patient have any of the following exclusions (please select all that apply)?		
☐ Gastroparesis		
Hypoglycemia unawareness (i.e. inability to detect and act upon the signs or symptoms of hypoglycemia)		
Severe hypoglycemia that required assistance during the past 6 months		
The patient requires drug therapy to stimulate gastrointestinal motility		
□ None of the above		

Prescriber Signature

Date

EOC ID:

Tafinlar-6 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing ther	apy?		
☐ Initial therapy	Continuing therapy		
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY):			
Q3. Please indicate the patient's diagnosis for	r the requested medication:		
Melanoma (unresectable or metastatic) in	a patient with BRAF V600E mutation (single agent therapy)		
Melanoma (unresectable or metastatic) in patients with BRAF V600E or V600K mutation (in combination with trametinib [Mekinist])			
Non-small cell lung cancer, Metastatic with BRAF V600E mutation, in combination with trametinib			
Anaplastic thyroid carcinoma, Locally adv	anced or metastatic, with BRAF V600E mutation, in combination with		
trametinib			
Other			
Q4. If the patient's diagnosis is OTHER, please specify below:			
Q5. Does the patient have a positive BRAF V600E or V600K mutation as detected by an FDA-approved test?			
☐ Yes	□ No		
Q6. Does the patient have wild-type BRAF melanoma?			
🗌 Yes	□ No		

EOC ID:

Tafinlar-6 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Q7. Is the requested medication being prescribed by an oncologist?		
Yes	□ No	

Prescriber Signature

Date

EOC ID:

Tagrisso-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

-			
Q1. Is this request for initial or continuing therapy?			
Initial therapy	Continuing therapy		
Q2. If the request is for CONTINUING THERAPY, please	provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested medication:			
Non-small cell lung cancer (NSCLC), metastatic	Other		
Q4. If the patient's diagnosis is OTHER, please specify below:			
Q5. Was the patient's diagnosis confirmed by an FDA-approv	ved test?		
☐ Yes	□ No		
Q6. Please select if any of the following apply to this patient:			
The disease is metastatic EGFR mutation-positive			
There is confirmed presence of T790M EGFR tumor mutation			
The patient's disease has progressed on or after EGFI	R tyrosine kinase inhibitor based therapy		

EOC ID:

Tagrisso-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Takhzyro-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested medication:		
Hereditary angioedema (prophylaxis)	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the patient 12 years of age or older?		
	No	

EOC ID:

Takhzyro-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
Prescriber Signature	Date

EOC ID:

Talzenna-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Breast cancer (locally advanced or metastatic)	Other	
Q4. If the patient's diagnosis is OTHER, please specify be	low:	
Q5. Does the patient have presence of a deleterious or suspe	ected deleterious germline BRCA-mutation (gBRCAm)?	
☐ Yes	□ No	
Q6. Is the patient's disease human epidermal growth factor receptor 2 (HER2)-negative?		
☐ Yes	□ No	
Q7. Is the requested medication prescribed by (or in consultation with) an oncologist?		
☐ Yes	□ No	
Q8. Is the patient 18 years of age or older?		

EOC ID:

Talzenna-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
☐ Yes	□ No

Prescriber Signature

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Date

EOC ID:

Tasigna-5 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
Initial therapy	Continuing therapy
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested medication: *	
 Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase (newly diagnosed) Chronic phase (CP) and accelerated phase (AP) Ph+ CML Other 	
Q4. Is the patient resistant to or intolerant to prior therapy ?	
☐ Yes	□ No
Q5. If the patient's diagnosis is OTHER, please specify below:	
Q6. Is the requested medication being prescribed by an oncologist?	
☐ Yes	□ No

EOC ID:

Tasigna-5 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Tegsedi-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please specify the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Polyneuropathy of hereditary transthyretin-mediated amyloidosis	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the patient 18 years of age or older?		
	□ No	
Q6. Is the patient enrolled in the Tegsedi REMS program?		
☐ Yes	□ No	
Q7. Do any of the following apply to the patient (please check all that apply)?		
□ Platelet count is below 100 x 10(9)/L		
Documented history of acute glomerulonephritis caused by inotersen		
None of the above		

EOC ID:

Tegsedi-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Testosterone-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name ((if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
☐ Initial therapy	Continuing therapy
Q2. For CONTINUING THERAPY, please indicate Start Da	ite (MM/YY):
Q3. Please indicate the patient's diagnosis below:	
Deficiency or absence of endogenous testosterone	
U Other	
Q4. If the patient's diagnosis is OTHER, please specify below	SW:
Q5. Do any of the following apply to this patient (please selec	t all that apply)?
Patient is female	
Patient has prostate cancer	
Patient has breast cancer	
None of the above	
Q6. Please indicate the patient's testosterone level PRIOR to start of therapy:	
Total testosterone GREATER than 300 ng/dL, free or bioa	available testosterone GREATER than 5 ng/dL
Total testosterone LESS than 300 ng/dL, free or bioavaila	ble testosterone LESS than 5 ng/dL

EOC ID:

Testosterone-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:

Absence of endogenous testosterone

□ None of the above

Prescriber Signature

Date

EOC ID:

Tetrabenazine-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?			
Initial therapy	Continuing therapy		
Q2. For continuing therapy, please specify start date (MM/YY):			
Q3. Please indicate the patient's diagnosis for the requested	medication: *		
Chorea associated with Huntington disease	☐ Other		
Q4. If the patient's diagnosis is OTHER, please specify below:			
Q5. Does the patient have any of the following EXCLUSIONS (please select all that apply)?			
Untreated or inadequately treated depression			
Actively suicidal			
History of hepatic disease			
Concurrent use of MAO inhibitors			
Concurrent use of reserpine (or it has been less than 20 days since reserpine was discontinued)			

EOC ID:

Tetrabenazine-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Thalomid-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Multiple myeloma, newly diagnosed		
Acute treatment of the cutaneous manifestations of mode	erate to severe erythema nodosum leprosum	
Severe erythema nodosum leprosum with cutaneous ma	inifestations	
Other		
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the requested medication being prescribed by an once	alagist or infectious disease specialist?	
	•	
	No	
Q6. If the diagnosis is multiple myeloma, will the patient receive concurrent dexamethasone?		
☐ Yes	No	
Q7. If the patient has a diagnosis of severe erythema nodosum leprosum and also has moderate to severe neuritis, will Thalomid be used as monotherapy?		

EOC ID:

Thalomid-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
 Yes No The patient does not have moderate to severe neuritis 	5	
Q8. Will the patient be monitored for signs and symptoms	of venous thromboembolism?	
☐ Yes	□ No	
Q9. Is the patient pregnant?		
Yes No	□ Not applicable	
Q10. Have male and female patients of child-bearing potential been instructed on the importance of proper utilization of appropriate contraceptive methods?		
☐ Yes	□ No	
Q11. Is the patient 12 years of age or older?		
Yes	□ No	

Prescriber Signature

Date

EOC ID:

Tibsovo-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Acute myeloid leukemia (AML), relapsed or refractory	Other	
Q4. If the patient's diagnosis is OTHER, please specify be	low:	
Q5. Does the patient have a susceptible isocitrate dehydroge	enase-1 (IDH1) mutation?	
	□ No	
Q6. Is the requested medication prescribed by (or in consultation with) an oncologist or hematologist?		
☐ Yes	□ No	
Q7. Is the patient 18 years of age or older?		
☐ Yes	□ No	

EOC ID:

Tibsovo-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Tracleer-6 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please p	provide the start date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Pulmonary arterial hypertension (PAH)	Other	
Q4. If the patient's diagnosis is OTHER, please specify below	DW:	
Q5. Has the diagnosis of PAH been confirmed by either of the following?		
Right heart catheterization		
Doppler echocardiogram (if patient is unable to undergo a right heart catheterization)		
None of the above		
Q6. Does the patient have World Health Organization (WHO) Group 1 and New York Heart Association (NYHA) Functional Class II-IV symptoms?		
	□ No	
Q7. FOR FEMALE PATIENTS OF CHILD-BEARING POTENTIAL, has pregnancy been excluded prior to therapy and patient will use two forms of reliable contraception during therapy?		

EOC ID:

Tracleer-6 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Yes		
No N/A - patient is not a female of child-bearing potential		
Q8. Does the patient have aminotransferase elevations accompanied by signs or symptoms of liver dysfunction or injury or bilirubin at least 2 times the upper limit of normal (ULN)?		
☐ Yes	□ No	
Q9. Will the patient be receiving concomitant cyclosporine A or glyburide therapy?		
□ Yes □ No		

Prescriber Signature

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

Date

EOC ID:

Tymlos-4 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
☐ Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please p	provide the start date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested medication:		
	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the patient a post-menopausal female at high risk for fracture?		
	□ No	
Q6. Is the patient at least 18 years of age or older?		
	□ No	
Q7. Has the patient experienced a prior fragility fracture?		
	□ No	
Q8. Does the patient have any of the following risk factors for fracture (please select all that apply)?		
Advanced age	Rheumatoid arthritis	

EOC ID:

Tymlos-4 Medicare

Phone: 800-361-4542

Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Parental history of fracture	Chronic steroid use	
Low body mass index (BMI)	Other secondary cause of osteoporosis	
Current smoker	None of the above	
Chronic alcohol use		
Q9. Has the patient failed an adequate trial of a bisphosphonate (one year) or has a contraindication or intolerance to a bisphosphonate trial?		
☐ Yes	□ No	

Prescriber Signature

Date

EOC ID:

Uptravi-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please p	provide the start date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested in	medication:	
Pulmonary arterial hypertension (PAH) (WHO Group I)	Other	
Q4. If the patient's diagnosis is OTHER, please specify bel	ow:	
Q5. Has the patient's diagnosis been confirmed by right heart catheterization?		
	□ No	
Q6. Has the patient tried and had an insufficient response to at least one other PAH agent (e.g. sildenafil)?		
	□ No	
Q7. Is the patient 18 years of age or older?		
☐ Yes	□ No	

EOC ID:

Uptravi-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Venclexta-6 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
☐ Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please indicate the start	date: (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested m	nedication: *	
Acute myeloid leukemia (AML), newly diagnosed		
Chronic lymphocytic leukemia (CLL)/small lymphocytic lym	nphoma (SLL) (with or without 17p deletion)	
Q4. For NEWLY DIAGNOSED AML, please select all that a	pply to this patient:	
☐ The patient is 75 years of age or older		
The patient cannot use intensive induction chemotherapy		
Venclexta will be used in combination with azacitadine, decitabine, or low-dose cytarabine		
None of the above		
Q5. For CLL/SLL, has the patient received at least one (1) prior therapy?		
☐ Yes	□ No	
Q6. If the patient's diagnosis is OTHER, please specify below:		

EOC ID:

Venclexta-6 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Date

Prescriber Signature

EOC ID:

Verzenio-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:	Address:	
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please	provide the start date (MM/YY):	
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Breast cancer (advanced or metastatic)	Other	
Q4. If the patient's diagnosis is OTHER, please specify be	elow:	
Q5. For BREAST CANCER, please select all that apply to th	is patient's disease:	
The patient's disease is hormone receptor (HR)-positive		
☐ The patient's disease is human epidermal growth factor receptor 2 (HER2)-negative		
None of the above		
Q6. For BREAST CANCER, please select all that apply to th	is patient's treatment:	
Verzenio will be used as monotherapy		
Verzenio will be used in combination with fulvestrant (Faslodex)		
Verzenio will be used as initial endocrine-based treatment in combination with an aromatase inhibitor		
The patient's disease has progressed following endoc		
The patient has already received at least one prior che	emotherapy regimen of Ibrance or Kisqali	

EOC ID:

Verzenio-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
None of the above	
Q7. Is the medication being prescribed by (or in consultat	ion with) an oncologist?
☐ Yes	□ No
Q8. Is the patient 18 years of age or older?	
☐ Yes	□ No

Prescriber Signature

Date

EOC ID:

Vitrakvi-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Continuing therapy		
t date (MM/YY):		
medication:		
Other		
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Is the patient's tumor neurotrophic receptor tyrosine kinase (NTRK) gene fusion positive without a known acquired resistance mutation?		
□ No		
The patient's disease is metastatic, or surgical resection is likely to result in severe morbidity		
atient has progressed following treatment)		
Q7. Is the requested medication being prescribed by (or in consultation with) an oncologist?		
□ No		

EOC ID:

Vitrakvi-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Vizimpro-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
☐ Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested	medication:	
Non-small cell lung cancer (NSCLC), metastatic	Other	
Q4. If the patient's diagnosis is OTHER, please specify be	ow:	
Q5. Is the patient's disease positive for epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 (L858R) substitution mutations as detected by an FDA approved test?		
☐ Yes	□ No	
Q6. Is the medication being prescribed by (or in consultation	with) an oncologist?	
	□ No	
Q7. Is the patient 18 years of age or older?		
☐ Yes	□ No	

EOC ID:

Vizimpro-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Xalkori-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial Therapy	Continuing Therapy	
Q2. If the request is for CONTINUING THERAPY, please p	provide the start date (MM/YY):	
Q3. Please indicate the diagnosis for which the requested me	edication is being prescribed:	
Non-small cell lung cancer, Metastatic, ALK-positive		
Non-small cell lung cancer, Metastatic, ROS1-positive		
Q4. If diagnosis is OTHER, please specify below:		
Q5. Is the prescribing physician an oncologist?		
☐ Yes	□ No	

EOC ID:

Xalkori-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Date

Prescriber Signature

EOC ID:

Xeljanz-5 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
Initial therapy	Continuing therapy
Q2. If the request is for CONTINUING THERAPY, please	provide the start date (MM/YY):
Q3. Please indicate the patient's diagnosis for the requested	medication:
Rheumatoid arthritis (moderately to severely active)	
Psoriatic Arthritis	
Other	
Q4. FOR Ulcerative Colitis: Is the patient corticosteroid de without a return of the symptoms of UC)?	pendent (ie, an inability to successfully taper corticosteroids
☐ Yes	□ No
Q5. If the patient's diagnosis is OTHER, please specify be	low:
Q6. Has the patient had failure, contraindication, or intolerand	ce to any of the following? (please select all that apply):
Methotrexate	
Enbrel (etanercept)	
🗌 Humira (adalimumab)	

Xeljanz-5 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Oral aminosalicylate		
Oral corticosteroid		
Azathioprine		
6-mercaptopurine		
□ None of the above		
Q7. If the patient has NOT tried any of the medications listed in the previous question, is there a reason these medications cannot be used (i.e. contraindication, history of adverse event, etc)?		
Q8. Does the patient have a documented needle-phobia to the degree that the patient has previously refused any injectable therapy or medical procedure? (refer to DSM-IV-TR 300.29 for specific phobia diagnostic criteria)		
☐ Yes	□ No	
Q9. Will the patient be receiving any of the following while	e taking Xeljanz?	
A biologic DMARD (such as Enbrel (etanercept), H (golimumab))	umira (adalimumab), Cimzia (certolizumab), Simponi	
A potent immunosuppressant (such as azathioprine or cyclosporine)		
□ None of the above		
Q10. Is the requested medication prescribed by (or in consultation with) a rheumatologist or gastroenterologist?		
☐ Yes	□ No	

Prescriber Signature

Date

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

EOC ID:

Xgeva-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
☐ Initial therapy	Continuing therapy	
Q2. For continuing therapy, please specify start date (N	/M/YY):	
Q3. Please indicate the patient's diagnosis for the request	ted medication:	
Bone metastases from solid tumors		
Giant cell tumor of the bone that is unresectable or where surgical resection is likely to result in severe morbidity		
Hypercalcemia of malignancy refractory to bisphosphonate therapy		
Prevention of skeletal related events in patients with multiple myeloma		
Other		
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Does the patient have uncorrected hypocalcemia?		
∏Yes	□ No	

EOC ID:

Xgeva-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Xolair-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
☐ Initial therapy	Continuing therapy
Q2. If the request is for CONTINUING THERAPY, please p	rovide the start date (MM/YY):
Q3. What is the patient's diagnosis for the requested medicati Chronic idiopathic urticaria Moderate to severe persistent allergic asthma Other	on? *
Q4. FOR URTICARIA, does the patient remain symptomati	c despite H1 antihistamine treatment?
☐ Yes	□ No
Q5. FOR CONTINUING THERAPY: Has a demonstrated in	nprovement in asthma control been noted?
☐ Yes	□ No
Q6. FOR ASTHMA, please select all that apply to this patie	nt:
blood test (i.e. radioallergosorbent test) for a specific IgE of Pretreatment serum IgE levels are greater than 30 a	and less than 1300 IU/mL ith high-dose inhaled corticosteroid (ICS) plus long-acting

EOC ID:

Xolair-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
has a contraindication to ICS or LABA	
Q7. If the patient's diagnosis is OTHER, please specify	/ below:
Q8. Please indicate the patient's age below:	
Under 6 years	6 years or older
Q9. Please indicate the prescriber's specialty below:	
Allergist	
🗌 Immunologist	
Pulmonologist	
Dermatologist	
Other	
Q10. If the prescriber's specialty is OTHER, please spe	ecify:

Prescriber Signature

Date

EOC ID:

Xospata-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?	
Initial therapy	Continuing therapy
Q2. For CONTINUING THERAPY, please provide the star	rt date (MM/YY):
Q3. Please indicate the patient's diagnosis for the requested	medication:
Acute myeloid leukemia, relapsed or refractory	Other
Q4. If the patient's diagnosis is OTHER, please specify be	elow:
Q5. Are FLT3 mutations present as detected by an FDA-app	roved test?
☐ Yes	□ No
Q6. Is the patient 18 years of age or older?	
☐ Yes	□ No
Q7. Is the medication being prescribed by (or in consultation	with) an oncologist or hematologist?
☐ Yes	□ No

EOC ID:

Xospata-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
Prescriber Signature	Date

EOC ID:

Xtandi-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	(if applicable):

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing t	therapy?	
Initial therapy		Continuing therapy
Q2. If the request is for CONTINUING T	THERAPY, please provide	the start date (MM/YY):
Q3. Please indicate the patient's diagnosis	s for the requested medica	ation below:
Prostate Cancer (metastatic, castration	n-resistant)	
Prostate Cancer (non-metastatic, cast	ration-resistant)	
Other		
Q4. FOR Metastatic prostate cancer: Ha	as the patient tried and fa	iled Zytiga?
☐ Yes		No
Q5. If the patient has not tried Zytiga history of adverse event, etc)?	a, is there a reason this m	edication cannot be used (i.e. contraindication,
Q6. If diagnosis is OTHER, please spec	sify below:	
Q7. Please indicate the Prescriber's specia	alty:	
Oncologist	Urologist	□ None of the above

EOC ID:

Xtandi-2 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

] No
-

Prescriber Signature

Date

EOC ID:

Xuriden-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therap	ıy?	
☐ Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested medication:		
Hereditary orotic aciduria	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		

EOC ID:

Xuriden-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
---------------	------------------

hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document

EOC ID:

Xyrem-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For continuing therapy, please specify start date (MM/Y	(Y):	
Q3. Please indicate the patient's diagnosis for the requested r	nedication: *	
Excessive daytime sleepiness		
 Cataplexy (a condition characterized by weak or paralyzed) Other 	zed muscles) in patients with narcolepsy	
Q4. If the patient's diagnosis is OTHER, please specify belo	ow:	
Q5. Is that patient taking or receiving any of the following: anx benzodiazepines, or ethanol?	iolytics, sedatives, hypnotics, barbiturates,	
☐ Yes	□ No	
Q6. For CONTINUING THERAPY, has the patient experienced a decrease in daytime sleepiness and/or cataplexy?		
☐ Yes	□ No	

EOC ID:

Xyrem-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Prescriber Signature

Date

EOC ID:

Yonsa-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. For CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested medication below:		
Prostate Cancer (metastatic, castration-resistant)	Other	
Q4. If the patient's diagnosis is OTHER, please specify be	low:	
Q5. Will the requested medication be used in combination with methylprednisolone?		
	□ No	
Q6. Has the patient tried and failed (or has an intolerance or contraindication to) Zytiga (abiraterone)?		
☐ Yes	□ No	
Q7. Is the patient 18 years of age or older?		
	□ No	
Q8. Is the medication being prescribed by (or in consultation with) an oncologist or urologist?		

EOC ID:

Yonsa-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:
☐ Yes ☐ No	

Prescriber Signature

Date

EOC ID:

Zejula-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested	d medication:	
Ovarian cancer (recurrent, epithelial)		
☐ Fallopian tube cancer (recurrent)		
Primary peritoneal cancer (recurrent) Other		
Q4. If the patient's diagnosis is OTHER, please specify b	elow:	
Q5. Has the patient had a complete or partial response to p	latinum-based chemotherapy?	
☐ Yes	□ No	
Q6. Is Zejula being prescribed by (or in consultation with) an oncologist or gynecologist?		
☐ Yes	□ No	
Q7. Is the patient 18 years of age or older?		
☐ Yes	No	

EOC ID:

Zejula-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Prescriber Signature

Date

EOC ID:

Zykadia-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:	
Member/Subscriber Number:	Fax:	Phone:
Date of Birth:	Office Contact:	
Group Number:	NPI:	State Lic ID:
Address:	Address:	
City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please provide the start date (MM/YY):		
Q3. What is the patient's diagnosis for the requested medication: *		
Anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC)	☐ Other	
Q4. If the patient's diagnosis is OTHER, please specify belo	DW:	

Zykadia-3 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

Patient Name:	Prescriber Name:
---------------	------------------

EOC ID:

Zytiga-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:	Prescriber Name:		
Member/Subscriber Number:	Fax:	Phone:	
Date of Birth:	Office Contact:		
Group Number:	NPI:	State Lic ID:	
Address:	Address:		
City, State ZIP:	City, State ZIP:	City, State ZIP:	
Primary Phone:	Specialty/facility name	Specialty/facility name (if applicable):	

*Please note that Envision will process the request as written, including drug name, with no substitution.

Expedited/Urgent

Drug Name and Strength:

Directions / SIG:

Q1. Is this request for initial or continuing therapy?		
Initial therapy	Continuing therapy	
Q2. If the request is for CONTINUING THERAPY, please specify the start date (MM/YY):		
Q3. Please indicate the patient's diagnosis for the requested medication:		
Metastatic prostate cancer (castration-resistant or high-risk castration-sensitive)	Other	
Q4. If the patient's diagnosis is OTHER, please specify below:		
Q5. Will Zytiga be used combination with prednisone?		
	□ No	

EOC ID:

Zytiga-1 Medicare

Phone: 800-361-4542 Fax back to: 877-503-7231

Rx manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:

Prescriber Name:

Date

Prescriber Signature